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ABSTRACT 
 
It has been recently demonstrated that the cytokine interleukin (IL)-6 is 
unique among the so called “inflammatory cytokines” in that it can be 
rapidly produced by and released from contracting skeletal muscle into the 
circulation in the absence of muscle damage or markers of inflammation. 
Moreover, previous studies have also indicated that the muscle-derived 
IL-6 may play an important role in insulin sensitivity and fat metabolism, 
which may help to explain some of the beneficial effects associated with 
exercise. Despite the fact that the magnitude of the contraction mediated 
IL-6 gene expression is often dependent on the mode, intensity and 
duration of the exercise bout performed, the signalling events that 
mediate these processes are poorly understood. Accordingly, the central 
aim of this thesis of work was to identify the signalling pathways for IL-6 
gene transcription in contracting skeletal muscle. We firstly sought to 
examine the cellular origin and distribution of IL-6 within the mass of 
skeletal muscle in response to exercise. Confirming that skeletal myocytes 
are a source of the exercise-induced elevation in IL-6 in human skeletal 
muscle by demonstrating that IL-6 mRNA increases intramyocellularly 
using in situ hybridisation, we next investigated the pattern of cytokine 
gene expression in response to contraction. Our data revealed that 
cytokines are not ubiquitously expressed in human skeletal muscle, and 
the expression of IL-6 and -8 are both influenced by glycogen availability 
within the contracting muscle. Moreover, a reduction in intramuscular 
glycogen also led to a marked phosphorylation of the nuclear p38 MAPK, 
2 
which was then proven to have a critical role in the mRNA induction of IL-
6. Importantly, the transcriptional activation of IL-6 in skeletal muscle 
appeared to be regulated by a NFκB-independent mechanism, and that 
NFAT inhibition may have a sensitizing effect on the skeletal muscle to 
Ca2+ stimulation. 
 
In summary, studies from this thesis suggest that contracting skeletal 
muscle cells actively produces IL-6 via a mechanism that is atypical from 
those seen during inflammation. It is clear from this series of studies that 
IL-6 is produced in muscle cells by a unique pathway that involves 
changes in metabolic and contractile processes, but not inflammatory 
signalling cascades. 
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CHAPTER ONE 
 
 
 
INTRODUCTION AND LITERATURE REVIEW 
 
4 
1.1 General introduction 
It has been well demonstrated that physical exercise induces considerable 
changes in physiological homeostasis (Pedersen and Hoffman-Goetz, 
2000). The discovery that cytokines are markedly increased in the 
circulation during exercise has lead to a great deal of attention within the 
scientific community in the recent years. Early studies on the systemic 
appearance of cytokines mainly came from various models of sepsis and 
inflammation. In these models, the local production of pro-inflammatory 
cytokines namely, tumour necrosis factor-α (TNF-α) and interleukin-1β 
(IL-1β) (Dinarello, 1992) result in systemic appearance of anti-
inflammatory cytokines and cytokine inhibitors like interleukin-6 (IL-6), 
interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-1ra) and 
soluble tumour necrosis factor receptor (sTNF-R) (Akira et al., 1993). 
Among these molecules, IL-6 is unique in that it has been reported to 
have both pro- and anti-inflammatory properties and its functional role 
appears to be context specific (Taaffe et al., 2000; Tilg et al., 1997).  
 
The first study to establish a link between exercise and cytokine response 
was performed by Cannon et al. in 1983, in which they saw an elevated 
rectal temperature in rats that resembles an infection, following injection 
of post-exercise plasma from human subjects. Since then, various studies 
have consistently reported the elevation of circulating cytokine levels, 
particularly IL-6, in response to different forms of exercise (Bruunsgaard 
et al., 1997; Cannon et al., 1986; Castell et al., 1997; Drenth et al., 
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1995; Evans et al., 1986; Hellsten et al., 1997; Nehlsen-Cannarella et al., 
1997b; Northoff and Berg, 1991; Ostrowski et al., 1998a; Ostrowski et 
al., 1999; Ostrowski et al., 1998b; Sprenger et al., 1992; Ullum et al., 
1994; Venkatraman and Pendergast, 1998). Following the onset of 
exercise, IL-6 is the first cytokine to appear in circulation with a 
magnitude of greater than 100-fold has been observed during exercise 
(Febbraio and Pedersen, 2002; Fischer, 2006; Pedersen and Hoffman-
Goetz, 2000; Pedersen et al., 2001). This increase is then accompanied by 
the emergence of cytokine inhibitors IL-1 receptor antagonist (IL-1ra), 
soluble tumour necrosis factor receptor (sTNF-R) and the anti-
inflammatory cytokine, interleukin-10 (IL-10) (Ostrowski et al., 1998a; 
Ostrowski et al., 1999; Ostrowski et al., 1998b), while the classic pro-
inflammatory cytokines TNF-α and IL-1β remained either unaffected with 
exercise (Petersen and Pedersen, 2005) or exhibits relatively small, 
delayed increments (Suzuki et al., 2002). In addition, plasma interferon 
(IFN)-α and –γ do not appear to elevate in response to exercise, while 
endurance exercise seemed to induce a systemic release of granulocyte 
colony-stimulating factor (G-CSF), macrophage colony-stimulating factor 
(M-CSF), monocyte chemotactic protein 1 (MCP-1), and chemokines like 
interleukin (IL)-8, macrophage inflammatory protein (MIP)-1 alpha and 
MIP-1 beta, but suppresses IL-2 (Ostrowski et al., 2001; Suzuki et al., 
2002; Suzuki et al., 2000). Although, exercise may affect the plasma 
concentration of other cytokines, the increase of IL-6 is by far the most 
marked and its appearance precedes that of the other cytokines (figure 
1.1). 
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Figure 1.1 The plasma cytokine response to sepsis (A) and exercise (B) 
(Petersen and Pedersen, 2005). In sepsis, the pattern of cytokine 
response mainly consisted of TNF-α, IL-1β, IL-6, IL-1ra, TNF-R, and IL-10. 
In contrast, exercise results in a marked elevation of IL-6, in the absence 
(or minimal expression) of the pro-inflammatory cytokines namely TNF-α 
and IL-1. 
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1.2 Background of IL-6 
The cytokine IL-6, was first discovered and named interferon-β2 (IFN- β2) 
in 1980 by Weissenbach and colleagues (Weissenbach et al., 1980) during 
an effort to clone and characterize the interferon-β gene in human 
fibroblasts. The cytokine was subsequently named B-cell stimulatory 
factor-2 (Hirano et al., 1985), B cell differentiation factor, T cell-replacing 
factor, 26-kDa protein (Content et al., 1982; Haegeman et al., 1986), 
hybridoma growth factor (Brakenhoff et al., 1987a; Van Snick et al., 
1986), interleukin hybridoma plasmacytoma factor 1, plasmacytoma 
growth factor (Nordan et al., 1987), hepatocyte-stimulating factor 
(Gauldie et al., 1987), macrophage granulocyte-inducing factor 2, 
cytotoxic T cell differentiation factor (Takai et al., 1988) and 
thrombopoietein due to its biological functions. In 1989, when these 
variously named proteins were found to be identical on the basis of their 
amino acid and/or nucleotide sequences, the name IL-6 was settled upon 
(Akira et al., 1993; Song and Kellum, 2005). IL-6 is a member of a 
cytokine family that consists of leukemia inhibitory factor (LIF), ciliary 
neurotropic factor (CNTF), IL-11, oncostatin M (OSM) and cardiotrophin 1 
(CT-1). Members of this cytokine family contain four antiparallel α-helices 
termed A, B, C and D that are connected by two long, and one short, 
loops (Figure 1.2) (Heinrich et al., 2003; Song and Kellum, 2005). 
Although each of the IL-6 type cytokine is recognized by a specific 
receptor complex, they all share a common subunit, glycoprotein-130 (gp-
130) for signal transduction (Figure 1.3) (Gadient and Patterson, 1999; 
Hibi et al., 1996; Hirano et al., 1994).  
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In humans, the gene for IL-6 is located on chromosome 7p21 of 
approximately 5 kilobase (kb) in size (Sehgal et al., 1986), while it is 7 kb 
on chromosome 5 of the mouse genome (Mock et al., 1989). They both 
consist of five exons (Figure 1.4) and display a high degree of homology 
in the protein coding regions, as well as the 3’ and 5’ untranslated regions 
(Tanabe et al., 1988; Yasukawa et al., 1987; Zilberstein et al., 1986). IL-
6 is synthesized as a precursor of 212 amino acids, in which the 
hydrophobic signal sequence at the N-terminal is cleaved during post-
translational processing to obtain the mature IL-6 peptide containing 184 
amino acids (Hirano et al., 1985; Nordan et al., 1987; Simpson et al., 
1988a; Van Damme et al., 1987; Van Snick et al., 1986). Of interest, in 
concert with the full-length peptide, a truncated form of IL-6 lacking the 
signal-transducing domain (encoded by exon II) due to alternative splicing 
has also been reported in peripheral blood mononuclear cells (Kestler et 
al., 1995). Depending on the cellular origin and the amount of post-
translational modifications including N- and O-linked glycosylations, and 
phosphorylations that occurs at multiple serine residues, the molecular 
mass of the mature IL-6 peptide may vary between 21-30 kDa (Cayphas 
et al., 1987; Hirano et al., 1985; Hirano et al., 1986; Van Damme et al., 
1987; Van Damme et al., 1988). However, these modifications appeared 
to have minimal effect on the biological activity of IL-6, since recombinant 
IL-6 synthesized in prokaryotes is functionally indistinguishable from the 
natural form (Brakenhoff et al., 1987b; Geiger et al., 1988; Simpson et 
al., 1997; Simpson et al., 1988b; Van Damme et al., 1987). 
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Figure 1.2 Structures of IL-6 and OSM (Heinrich et al., 2003). The four 
helices A, B, C and D are highlighted in different colours; circles indicate 
the three receptor-binding domains. 
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Figure 1.3 Members of the IL-6-type cytokine family and their respective 
receptors (Heinrich et al., 2003). Each of the IL-6-type cytokine is 
recognized by a different ligand-binding subunit, but they all require the 
transmembrane gp130 subunit for signal transduction.  
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Figure 1.4 Structural comparison of the murine and human IL-6 genes 
(Tanabe et al., 1988). The five exons are represented by open (coding) 
and closed (non-coding) boxes. Numbers above/below the two genes 
indicate nucleotide base pair (bp) in each coding region of the exon and 
intron, respectively. Sequence homologies between human and murine in 
the coding region of each exon are indicated at the bottom of the 
diagram.  
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In healthy individuals, the resting plasma concentration of IL-6 is usually 
around 1 pg•ml-1 or less (Bruunsgaard et al., 1997; Ostrowski et al., 
1998a). The circulating concentration of this cytokine may peak to 100 
pg•ml-1, in response to exercise (Fischer, 2006), or a much higher 
concentration (10 000 pg•ml-1) has been observed in the case of severe 
systemic infections (Friedland et al., 1992). In contrast, chronic low-level 
increases in plasma IL-6 of 10 pg•ml-1 or less has been demonstrated in 
obesity (Bastard et al., 2000), sedentary individuals (Fischer et al., 2006; 
Panagiotakos et al., 2005), insulin resistance (Bruun et al., 2003), type 2 
diabetes (Kado et al., 1999) and cardiovascular disease (Fisman et al., 
2006), and may be used as a predictor of mortality (Bruunsgaard, 2002). 
 
1.3 Kinetics of the IL-6 response to exercise 
It has been well established that the plasma level of IL-6 may increase 
over 100-fold in response to strenuous exercise (Starkie et al., 2001b). 
While this may represent an atypical and exaggerated response to 
exhaustive exercise such as marathon running (Fischer, 2006), the 
kinetics of  IL-6 appearing in the circulation seems to differ based on three 
major factors: the mode, intensity and duration of exercise performed . 
For instance, Nielsen et al. (1996) demonstrated a twofold increase in the 
plasma concentration of IL-6 after 6 minutes of maximal rowing exercise. 
However, in running, the increase of plasma IL-6 was not seen until 30 
minutes after the onset of exercise, which was peaked after 2.5 hours of 
exercise (Ostrowski et al., 1998a). It is noteworthy that the exercise-
13 
induced increase in plasma IL-6 is not linear throughout the course of 
exercise, but rather is somewhat exponential as exercise progresses 
(Fischer et al., 2004a; Ostrowski et al., 1998a; Steensberg et al., 2000b).  
 
It is clear that the kinetics of the IL-6 response to exercise of concentric 
nature differs from that of eccentric nature, the latter of which is often 
associated with notable muscle damage (Bruunsgaard et al., 1997; 
Ostrowski et al., 1998b; Rohde et al., 1997). In concentric contractions, 
the increase of IL-6 in circulation has been demonstrated to be closely 
related to the duration of exercise, and the appearance of IL-6 in the 
plasma exhibits a logarithmic relationship to the duration of muscular 
activity (Ostrowski et al., 1998a). The maximal level of IL-6 for this type 
of contraction is usually observed either immediately post exercise or 
shortly thereafter, followed by a rapid decline towards pre-exercise level 
within a few hours (Fischer et al., 2004a; Ostrowski et al., 1998a). 
Conversely, the IL-6 level in response to “muscle damaging” (eccentric) 
exercise is of somewhat a lower magnitude, in which the peak level is 
often seen some time after the cessation of contraction and the plasma 
level may remain elevated for several days (Pedersen et al., 2001; Toft et 
al., 2002).    
  
1.4 The cellular origin of the exercise-induced IL-6 
In mammals, IL-6 is mainly produced by various cells of the immune 
system including activated monocytes/macrophages (Aarden et al., 1987; 
14 
Van Snick et al., 1986), fibroblasts (Weissenbach et al., 1980) and 
vascular endothelial cells (Corbel and Melchers, 1984). Moreover, other 
cells including T-cells (Hirano et al., 1985; Van Snick et al., 1986), 
keratinocytes (Baumann et al., 1984), osteoblasts, B-cells, neutrophils, 
eosinophils, mast cells, smooth muscle cells (Akira et al., 1993), 
folliculostellate cells in the anterior pituitary (Vankelecom et al., 1989), 
adipocytes (Arner, 2005; Trayhurn and Wood, 2004) and skeletal muscle 
cells (Nagaraju et al., 1998) are also known to produce IL-6 under various 
conditions. Given that exercise primarily involves muscular contraction 
from the various body parts, skeletal muscle was proposed to be a 
potential candidate for the exercise-induced increase in plasma IL-6 
(Febbraio and Pedersen, 2002). In 2000, Steensberg et al. (2000a) used a 
one legged knee extending model and showed a steady increase in 
systemic IL-6 concentration over the course of experiment. Intriguingly, 
when they compared the net IL-6 release from the two legs, IL-6 was 
observed to be significantly released from the contracting, but not the 
resting limb. Morerover, the kinentics of IL-6 release from the exercising 
leg closely matched the systemic concentration suggesting the contracting 
muscles are accountable for the systemic appearance of IL-6. 
 
In resting human skeletal muscle, the level of IL-6 mRNA appeared to be 
minimal, with a basal expression of the IL-6 protein predominantly found 
in the slow-twitch (type I) fibres (Plomgaard et al., 2005). Exercise rapidly 
increases the nuclear transcriptional rate of IL-6 within the contracting 
muscles, with a 10- to 20-fold increase in mRNA content observed 
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following 30 minutes of “non-damaging” exercise, which may attain its 
peak (up to 100-fold) immediately post-exercise (Keller et al., 2001a), 
while the protein of IL-6 have also been observed to be expressed 
uniformly across post-exercise muscle fibres (Penkowa et al., 2003).  
Together with the finding that exercise do not induce the IL-6 mRNA 
(Moldoveanu et al., 2000) or protein expression (Starkie et al., 2000a; 
Starkie et al., 2001a) in monocytes, which is often seen during sepsis 
(Pedersen and Hoffman-Goetz, 2000), these data seemed to suggest that 
skeletal myocytes may be responsible for making IL-6 during exercise. 
 
1.5 Regulation of the exercise-induced IL-6 response  
It is generally understood that the contraction induced IL-6 gene 
expression is related to the mode, intensity and duration of the exercise, 
and one’s endurance capacity (Febbraio and Koukoulas, 2000; Fischer, 
2006; Pedersen and Hoffman-Goetz, 2000; Pedersen et al., 2001). In the 
past, this response was hypothesized to be derived from the immune 
cells, based on the common belief that the exercise-induced IL-6 increase 
in the plasma is a consequence of an immune response from the injured 
working muscle (Nehlsen-Cannarella et al., 1997a). Recent studies, 
however, revealed that the cytokine response seen during exercise differs 
greatly from that of pathophysiologic nature (Figure 1.1) (Febbraio and 
Pedersen, 2002; Pedersen and Hoffman-Goetz, 2000; Pedersen et al., 
2001; Suzuki et al., 2002). The fact that exercise induces IL-6 increase in 
the circulation without observable markers of inflammation (TNF-α and IL-
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1β) or tissue injuries (Ostrowski et al., 1998a; Ostrowski et al., 1999) is 
linking IL-6 to biological processes other than inflammation. In most 
cases, exercise does not increase the circulating concentration of TNF-α 
and IL-1β which are the classic markers of inflammation (Febbraio and 
Pedersen, 2002; Pedersen and Hoffman-Goetz, 2000; Pedersen et al., 
2004b; Suzuki et al., 2002), but elevates the systemic concentration of 
anti-inflammatory cytokines and cytokine inhibitors like IL-10, sTNF-R and 
IL-1ra  (Ostrowski et al., 1999; Ostrowski et al., 2000; Pedersen et al., 
2004b). IL-6 appears to directly suppress the production of TNF-α both in 
vitro (Schindler et al., 1990) and in vivo (Matthys et al., 1995; Mizuhara 
et al., 1994) and IL-1β (Petersen and Pedersen, 2005; Rehman et al., 
1997). IL-6 also stimulates the production of IL-1ra and IL-10 which have 
been found to have negative effects on the production of IL-1α, IL-1β and 
TNF-α, as well as various chemokines (Moore et al., 1993; Pretolani, 
1999; Steensberg et al., 2003a). Furthermore, it has been demonstrated 
that exercise could negate the endotoxin-induced inflammatory response 
in humans (Starkie et al., 2003) and TNF-α overexpression in mice (Keller 
et al., 2004). Even in the context of eccentric exercise whereby the 
exaggerated muscular damage is represented by 1000-fold increase in the 
post-exercise plasma creatine kinase (CK) level, the concentration of 
circulating IL-6 was only elevated by 4-fold (Pedersen et al., 2001) 
compared to 30-fold during concentric exercise, (Steensberg et al., 
2001c) suggesting muscle damage is not required for the regulation of IL-
6 during exercise.  
 
17 
Ostrowski et al. (2000) has demonstrated a positive correlation between 
the magnitude of IL-6 response and exercise intensity which is a 
determining factor controlling the mass of muscle being recruited for 
contractile activity. Given that skeletal muscle is a major source of the 
circulating IL-6 seen during exercise (Fischer et al., 2004a; Steensberg et 
al., 2000b), it is therefore understandable why the most substantial 
increase of IL-6 is often observed in response to strenuous exercise that 
involves contraction of multiple large muscle groups, such as running 
(Nieman et al., 2005; Ostrowski et al., 1999; Suzuki et al., 2000). Of 
note, the effects of exercise intensity should always be considered 
together with duration of the exercise, since exercise of high intensity is 
often associated with a shorter duration and there appeared to be an 
inverse relationship existing between the two. However, exercise duration 
alone is believed to be an important factor that is accountable for over 
50% of the variation in post–exercise plasma IL-6 level (Fischer, 2006). 
Furthermore, regular exercise training have also been reported to lower 
the basal levels of plasma IL-6 (Cesari et al., 2004; Colbert et al., 2004; 
Panagiotakos et al., 2005), and markedly reduces the contraction-induced 
IL-6 mRNA expression in human skeletal muscle (Fischer et al., 2004b). 
Although, the exact mechanism awaits further investigation, it is possible 
that this phenomenon could be due to muscle adaptation to exercise 
training, since trained skeletal muscles have a higher pre-exercise 
glycogen content and substrate turn over rate (Schantz et al., 1983), as a 
result, they are more fatigue resistant and rely less on the extracellular 
substrates during exercise (Phillips et al., 1996).   
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1.6 Mechanisms for IL-6 production in skeletal muscle  
Although, the aforementioned factors may serve as extracellular signals to 
modulate the IL-6 response (Fischer, 2006), the fact that IL-6 is made 
and secreted only by the contracting muscles, and not the resting muscles 
that were subjected to the same blood supply (Ji et al., 2004; Steensberg 
et al., 2000b), indicates that the exercise induced IL-6 response is 
regulated by mechanisms other than those of endocrine origin. Indeed, a 
rapid increase in the nuclear transcriptional rate of IL-6 has been 
demonstrated in isolated muscle nuclei, following the onset of exercise 
(Keller et al., 2001b), and that the plasma IL-6 has also been observed to 
have a relatively short half-life (Montero-Julian et al., 1995; van Hall et 
al., 2003) suggesting transcriptional activation may play an important role 
in regulating the expression of IL-6 during exercise. 
 
The transcription regulatory region, also known as the promoter region, of 
IL-6 is located at the 5’ flanking region immediately upstream of the first 
coding exon. This promoter region contains cis-acting response elements 
that are important in dictating gene expression upon binding with 
transcription factors resulting from signalling pathway activation (Figure 
1.5). The importance of this region was highlighted, when the first 300 bp 
sequence of the human promoter was found to share greater than 80% 
homology with that of the mouse (Tanabe et al., 1988) suggesting its role 
in this region is of evolutionary importance. Using a site-directed 
mutagenesis approach, Dendorfer et al. (1994a) reported the mapping of 
potential transcription factor docking sites within the IL-6 promoter.  
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Figure 1.5 Schematic presentation of the IL-6 promoter showing the 
putative cis-regulatory elements of the human IL-6 promoter (Dendorfer 
et al., 1994b). The approximate locations of each response element, 
relative to the major transcription start site (+ 1), are indicated at the 
bottom of the diagram. Abbreviations: HLH, helix-loop-helix.  
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These included response elements for glucocorticoid receptor (GRE), 
activator protein-1 (AP-1), Ets family of transcription factors, GATA 
proteins, NFκB and a multiple response element (MRE) which comprised of 
elements for nuclear factor interleukin-6 (NF-IL-6) and cAMP response 
element binding protein (CREB). Of interest, both AP-1 and GATA proteins 
are known transcription partners of NFAT, their synergistic dimerization 
has been shown to enhance the transcriptional activity of NFAT on a 
variety of target genes (Im and Rao, 2004; Macian et al., 2001). 
Moreover, analysis of muscle biopsies from human subjects that had 
undergone one hour of cycling exercise demonstrated an increased 
nuclear abundance of both total and phosphorylated p38 MAPK, but the 
nuclear localization of NFAT was unaffected (McGee and Hargreaves, 
2004).  Of note, p38 MAPK is a known regulator of ATF-2 and Elk-1, in 
which ATF-2 is a subunit of the AP-1 heterodimer (Jun:ATF) (Derijard et 
al., 1995; Raingeaud et al., 1995; van Dam and Castellazzi, 2001), while 
Elk1 is a member of the Ets superfamily of transcription factors 
(Whitmarsh et al., 1995; Yordy and Muise-Helmericks, 2000). More 
importantly, in cultured murine muscle cells, p38 MAPK has been observed 
to induce the activity of NFκB and IL-6 gene expression by simultaneously 
reducing inhibitor of kappa B-alpha (IκB-α) levels and enhancing the DNA 
binding activity of NFκB, as well as potentiating the transactivating activity 
of the p65 subunit (Baeza-Raja and Munoz-Canoves, 2004). It is 
important to note that the activity of p38 MAPK is often increased in 
skeletal muscle following contraction (Boppart et al., 2000b; Goodyear et 
al., 1996b), and that the activation of p38 MAPK has been associated with 
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depleted intramusclar glycogen content and disrupted Ca2+ homeostasis 
resulting from prolonged exercise (Febbraio and Pedersen, 2002). 
Therefore, even though the IL-6 promoter does not appear to contain 
consensus response sequences for p38 MAPK, it is this kinase that is 
involved in the regulation of IL-6 expression through the transactivation of 
other transcription factors. In addition, p38 MAPK has also been 
associated with post-transcriptional mRNA stabilization of IL-6 via the 
action of its downstream target, p38 MAP kinase-activated protein kinase 
(MAPKAP K2 or MK2) (Patil et al., 2004; Wang et al., 1999; Winzen et al., 
1999). 
 
Although, the activity of NFκB can be regulated by the activation of p38 
MAPK, it should be brought to attention that NFκB per se is also a 
renowned transcriptional regulator of IL-6 (Liang et al., 2004a). NFκB is a 
redox- (reduction-oxidation) and oxygen-sensitive transcription factor that 
is known to be activated upon exposure to reactive oxygen species (ROS) 
(Haddad, 2002; Schreck et al., 1991). Increased ROS formation has been 
observed in the contracting muscles of both animal (Davies et al., 1982; 
Jackson et al., 1985; Sandstrom et al., 2006) and human models 
(Jackson, 2005; Smith and Reid, 2006) during exercise. In cultured C2C12 
myotubes, Kosmidou et al. (2002) demonstrated that ROS stimulated the 
production of IL-6 in a manner that involves transcriptional activation of 
the IL-6 gene through an NFκB/AP-1-dependent mechanism. 
Supplementation of different antioxidants have been shown to associate 
with a reduced expression of IL-6 both in vivo (Thompson et al., 2001; 
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Vassilakopoulos et al., 2003) and in vitro (Kosmidou et al., 2002). 
Inhibition of NFκB activation via oral administration of a non-steroidal 
anti-inflammatory drug, indomethacin, ablated the exercise-induced 
increase of plasma IL-6 in humans (Rhind et al., 2002). However, the 
activation of NFκB through muscle-specific transgenic expression of its 
upstream kinase, the IkappaB kinase beta (IκKβ) in mice did not increase 
the transcription of IL-6 in skeletal muscle (Cai et al., 2004), suggesting 
NFκB may not be solely responsible for the transcription of IL-6 gene in 
contracting muscle.  
 
It has been well established that mechanical load during contractile 
activity is a potent stimulus for Ca2+ release from the sarcoplasmic 
reticulum (Olson and Williams, 2000a). While elevated Ca2+ levels have 
been shown to activate nuclear factor of activated T-cells (NFAT) 
(Dolmetsch et al., 1998; Im and Rao, 2004; Olson and Williams, 2000a) 
and nuclear factor kappa B (NFκB) (Dolmetsch et al., 1998; Kubis et al., 
2003) in vitro, incubation of human muscle cells in culture or ex-vivo with 
a calcium ionophore also results in an increased expression of IL-6 
(Holmes et al., 2004; Keller et al., 2002a). Moreover, analysis of muscle 
biopsies from human subjects that had undergone one hour of cycling 
exercise demonstrated an increased nuclear abundance of both total and 
phosphorylated p38 MAPK, but unaltered nuclear localization of NFAT 
(McGee and Hargreaves, 2004), while the mRNA expression of calcineurin 
A, a serine/threonine phosphatase that is sensitive to elevated 
intracellular Ca2+, was increased in response to knee extensor exercise 
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(Pilegaard et al., 2003). NFAT is a transcription factor whose overall 
activity depends on the balance between dephosphorylation (activation) 
by calcineurin, and re-phosphorylation (de-activation) by NFAT kinases 
like the glycogen synthase kinase (GSK)-3 (Fiedler and Wollert, 2004). 
Therefore, it is possible that the lack of nuclear abundance of NFAT 
observed after exercise (McGee and Hargreaves, 2004), may be due to a 
rapid rephosphorylation of NFAT which resulted in a subtle nuclear 
localization. This notion is supported by a more recent study that 
observed nuclear localization of NFAT following a 20 minute stimulation 
with ionomycin, a potent calcium ionophore (Noguchi et al., 2004a). Of 
interest, it is known that muscle cell expresses high levels of NFAT (Olson 
and Williams, 2000a), and its activity is markedly upregulated in response 
to a low sustained elevation of cytosolic Ca2+ levels (Dolmetsch et al., 
1998; Febbraio and Pedersen, 2002). A low sustained elevation of 
intracellular Ca2+ is also a characteristic of prolonged muscular contraction 
(Konishi, 1998) suggesting NFAT signalling may be responsible for the 
contraction-mediated IL-6 synthesis. 
 
Although NFAT, in itself, can lead to cytokine gene transcription, in the 
nucleus, NFAT has been shown to interact with the transcription factor AP-
1 mediating the transcription of cytokine genes (Crabtree, 1999; Rao et 
al., 1997). It is possible that large intracellular Ca2+ transients seen during 
maximal contraction may also activate the transcription of IL-6 via NFκB 
and c-jun N-terminal kinase  (JNK)–dependent mechanism (Dolmetsch et 
al., 1998; Febbraio and Pedersen, 2002). The activation of JNK is 
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associated with IL-6 gene transcription in monocytes via the action of 
NFκB (Tuyt et al., 1999) and muscle contraction markedly increases JNK 
activation (Boppart et al., 2000b), whereby the downstream substrates of 
JNK are known to mediate transcription of cytokine genes via AP-1 
dimerization (Hibi et al., 1993). Taken together, although the involvement 
of these signalling pathways in the activation of IL-6 in skeletal muscle is 
yet to be determined, it is possible that during more intense muscular 
activity the serial activation of these pathways may give rise to the 
pronounced IL-6 response observed in the plasma. 
 
Besides the aforementioned mechanisms, intramuscular glycogen content 
has also been implicated in the contraction-induced increase in IL-6 gene 
transcription. In humans, a reduced intramuscular glycogen content has 
been shown to exacerbate the contraction-mediated increase in IL-6 gene 
transcription (Keller et al., 2001a; Steensberg et al., 2001a), and 
therefore its mRNA expression (Gleeson and Bishop, 2000; Steensberg et 
al., 2001b) and protein release (Steensberg et al., 2001b). Moreover, IL-6 
mRNA abundance (Febbraio et al., 2003b; Starkie et al., 2000b) and net 
contracting limb IL-6 protein release (Febbraio et al., 2003b) is reversed 
by the carbohydrate supplementation. Although, the signalling mechanism 
by which muscle glycogen enhances the transcription of IL-6 is yet to be 
determined, depletion of intramuscular glycogen content has been 
associated with a limited energy availability for the working muscles, 
which could have profound effects on a variety of cellular processes 
including gene transcription (Hargreaves, 2004). p38 MAPK is a stress-
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activated protein kinase (Ben-Levy et al., 1998) which is often activated in 
skeletal muscle during contraction (Boppart et al., 2000a; Goodyear et al., 
1996a; Williamson et al., 2003a), and low intramuscular glycogen content 
disrupts the uptake and release of calcium by the sarcoplasmic reticulum 
in both animals (Byrd et al., 1989; Chin and Allen, 1996; Stephenson et 
al., 1999) and humans (Booth et al., 1997). Taken together, these 
findings suggest that the reduced glycogen content during prolonged 
exercise may potentiate the transcription of IL-6 in the working muscles 
via a pathway cross-talk between Ca2+ and p38 MAPK (Febbraio and 
Pedersen, 2002; Febbraio and Pedersen, 2005) (Figure 1.6).  
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Figure 1.6 Schematic presentation of the proposed signalling cascades 
and biological effects of the muscle-derived IL-6. Altered Ca2+ 
homeostasis, depleted glycogen stores and increased formation of ROS 
are all capable of inducing the expression of IL-6 via activation of the 
stated signalling pathways. Once synthesized, IL-6 may act locally within 
the contracting skeletal muscle in an auto-/para-crine manner or be 
secreted into the circulation exerting a myriad of systemic effects.    
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1.7 Biological roles of muscle-derived IL-6 
As previously mentioned, one of the biological functions of muscle-derived 
IL-6 is to down-regulate the TNF-α and IL-1 induced inflammation (Figure 
1.6). This is thought to be one way physical activity may provide 
beneficial effects against chronic medical disorders associated with low-
grade inflammation such as atherosclerosis and Type 2 diabetes, as well 
as various forms of cancers (Blair et al., 2001; Petersen and Pedersen, 
2005). Recent studies have suggested that muscle derived-IL-6 may act 
as a hormone and play an important role in energy metabolism (Febbraio 
and Pedersen, 2002; Pedersen et al., 2004a; Pedersen et al., 2001; 
Petersen and Pedersen, 2005). It is known that physical exercise rapidly 
increases glucose uptake and utilization by the working skeletal muscles. 
This results in a sudden fall of the blood glucose level (hypoglycaemia) 
which then triggers the production and release of glucose from the liver, 
in order to maintain blood glucose homeostasis (euglycaemia) (Kjaer, 
2001). Despite intensive research into the possible pathways that may be 
involved in this process, very little is known regarding the regulation of 
hepatic glucose production during exercise. It has been demonstrated that 
exercise alters the circulating levels of various endocrine hormones 
including insulin and glucagon (Kjaer, 2001), cortisol (Cryer, 1993), 
adrenaline (Howlett et al., 1999), as well as adrenergic neural stimulation 
(Sigal et al., 2000; Sigal et al., 1994). However, none of these factors 
seem to fully account for the rise in hepatic glucose production during 
exercise (Pedersen et al., 2001), which raised a possibility that other 
factor(s) such as IL-6, released from the working muscle cells may 
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contribute to the increase in hepatic glucose production (Howlett et al., 
1999).   
 
IL-6 has been shown to have a marked influence on hepatic glucose 
metabolism by the inhibition of glycogen synthase and activation of 
glycogen phosphorylase, which are the rate-limiting enzymes in 
glycogenolysis (Kanemaki et al., 1998). Moreover, infusion of human 
subjects with recombinant human IL-6 (rhIL-6) also resulted in an 
increase in the hepatic glucose production (Stouthard et al., 1995), as 
well as the fasting blood glucose level in a dose-dependent manner 
(Tsigos et al., 1997). However, these data were collected from patients 
with renal cell carcinoma (Stouthard et al., 1995) or involved patho-
physiological infusions of IL-6 (Tsigos et al., 1997). In subsequent studies 
that infused physiological levels of IL-6 at rest, no increase in hepatic 
glucose production was observed (Steensberg et al., 2003b). However, in 
2004 Febbraio et al. (2004) demonstrated that IL-6 indeed contributed to 
the exercise-induced increase in hepatic glucose production, 
demonstrating that IL-6 indeed signalled from muscle to liver during 
exercise. This study identified skeletal muscle as an endocrine organ and 
IL-6 as the first “myokine”. Since, these data were in contrast to those 
data obtained by this group at rest (Steensberg et al. 2003), these 
authors concluded that IL-6 requires a “co-factor” produced during 
exercise to increase liver glucose output.    
 
29 
Along with the observation on the hepatic glucose output, Stouthard et al. 
(1995) also reported an elevated level of circulating free fatty acids (FFAs) 
during rhIL-6 infusion in their patient population. IL-6 infusion into rats 
have also been found to elevate the serum levels of triglyceride and FFAs 
resulting from an increased hepatic triglyceride secretion and lipolysis, 
respectively (Nonogaki et al., 1995). In more recent studies, IL-6 infusion 
into healthy humans (van Hall et al., 2003) and patients with type 2 
diabetes (Watt et al., 2005) has been shown to result in an increase in 
lipolysis, fatty acid uptake and whole body fatty acid oxidation. 
Interestingly, a study by Wallenius et al. (2002) demonstrated that IL-6 
deficient mice developed mature-onset obesity that is reversible by 
exogenous supplementation suggesting that IL-6 is a powerful lipolytic 
factor, and raise a possibility that the elevated circulating concentration of 
FFA during exercise may be partly mediated by the muscle derived IL-6 
(Figure 1.6).   
 
IL-6 has also been shown to improve glucose absorption in the gut 
(Hardin et al., 2000), and the administration of IL-6 also appeared to have 
a positive effect on glucose uptake by insulin sensitive tissues (Figure 1.6) 
(Stouthard et al., 1996). While a polymorphism of the IL-6 gene has been 
linked to an altered insulin sensitivity in humans (Fernandez-Real et al., 
2000), mice with transgenic disruption of the IL-6 gene developed 
impaired glucose tolerance which was reverted by exogenous 
supplementation of IL-6 (Wallenius et al., 2002). Taken together, the 
muscle-derived IL-6 appears to act in an endocrine hormone-like manner, 
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maintaining energy homeostasis by mobilising substrate uptake and 
release in different tissues.  
 
Besides the endocrine effect of IL-6, this cytokine has also been suggested 
to be involved in local processes occur that within the producing muscle 
(Figure 1.6). Exogenous IL-6 has been shown to have proliferative effects 
on both human myoblast and satellite cells, and that the proliferation of 
satellite cells is regulated by the endogenous production of IL-6 in an 
autocrine manner (Austin et al., 1992; Austin and Burgess, 1991; Cantini 
et al., 1995). Together with the finding that IL-6 treatment of myoblasts 
enhances their differentiation in culture (Okazaki et al., 1996) has led to 
suggestion that the locally produced IL-6 may be implicated in muscle 
hypertrophy seen in resistance exercise (Vierck et al., 2000).   
 
In summary, the literature demonstrates that contracting skeletal muscles 
actively produce and release IL-6 into the circulation independent of 
inflammation. It appears that the elevated Ca2+ levels seen during muscle 
contraction may play a regulatory role in this process, however the exact 
intracellular mechanism is yet to be characterized, and it is likely to 
involve pathway crosstalk. This thesis sought to investigate the 
intracellular signalling pathway for interleukin-6 gene transcription in 
skeletal muscle.  
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AIMS OF THE THESIS 
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2.1 Aims of the thesis 
The primary aim of this thesis was to determine the intracellular 
regulatory mechanism mediating the expression of the IL-6 gene in 
skeletal muscle. Such investigation encompassed the study of in vivo and 
in vitro (human and cell culture) models utilizing a variety of well-
established analytical techniques. 
 
It is known that acute skeletal muscle contraction elicits a rapid elevation 
of IL-6 in the plasma through a rapid rate of gene transcription, 
translation and release of the IL-6 protein from skeletal muscles. 
However, the cellular source of IL-6 within skeletal muscle tissue during 
contraction has yet to be clearly elucidated. The first study (Chapter 3) 
investigated whether skeletal myocytes per se is a source of the 
contraction-induced IL-6. After confirming the cellular origin of the 
contraction-induced IL-6, the second study (Chapter 4) examined the 
effect of intramuscular glycogen levels on the expression of cytokine 
genes in skeletal muscle.     
 
The intracellular signalling events in relation to altered glycogen levels and 
contraction were then investigated in muscle biopsy samples of post-
exercise human subjects. The third study (Chapter 5) aimed to 
characterize the regulatory mechanisms involved in the regulation of IL-6 
during exercise in both normal and glycogen-depleted states. Given that 
the literature has suggested the possible involvement of both elevated 
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Ca2+ levels and activation of p38 MAPK in the regulation of IL-6 synthesis, 
the following study (Chapter 6) examined the effect of these factors on 
the expression of IL-6 in cultured skeletal muscle (myotubes). 
 
It has been demonstrated that the expression of IL-6 in muscle may also 
required the activation of intermediate molecules that are involved in the 
classic pro-inflammatory pathways, particularly those of the NFκB 
pathway. However, according to our findings (Chapter 5) and the 
literature, conflicting evidence seems to exist concerning the role of this 
pathway during muscle contraction. Therefore, the final study (Chapter 7) 
investigated the expression pattern of IL-6 and other closely associated 
cytokines in response to different stimuli in cultured skeletal myotubes, 
with particular focus on the role of NFκB in the regulation of IL-6 gene 
transcription. 
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SKELETAL MYOCYTES ARE A SOURCE OF 
INTERLEUKIN-6 mRNA EXPRESSION AND 
PROTEIN RELEASE DURING CONTRACTION 
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3.1 Introduction 
 
It is now well established that acute skeletal muscle contraction results in 
a rapid elevation of the plasma level of the cytokine, interleukin (IL)-6 
(Febbraio and Pedersen, 2002). This increase can be attributed to a rapid 
rate of gene transcription within skeletal muscle biopsy specimens (Keller 
et al., 2001b) and translation of IL-6 protein that is released from the 
contracting skeletal muscle (Steensberg et al., 2000b).  
 
The cellular source of IL-6 within skeletal muscle tissue during contraction 
has yet to be clearly elucidated. Given that skeletal muscle contains cell 
types other than myocytes, including smooth muscle cells, fibroblasts, 
endothelial cells, and macrophages, that are also known to produce IL-6 
(Cicco et al., 1990; De Rossi et al., 2000; Klouche et al., 1999; Podor et 
al., 1989). Therefore, it is possible that the elevation in IL-6 gene 
expression in biopsy tissue and IL-6 protein release could be originated 
from those cells. In accordance with this hypothesis, Malm et al. (2000) 
detected IL-6 protein in both muscle and non-muscle cells using 
immunohistochemical staining of muscle biopsies taken before and after 
acute contraction, while the group was unable to show any change in the 
amount of IL-6 protein as a result of muscle contraction. Recently, 
however, Penkowa et al. (2003) reported a qualitative elevation in IL-6 
protein measured in muscle cells within human muscle biopsy sections by 
immunohistochemistry. In that study, IL-6 was uniformly expressed 
throughout each fibre, and the authors also stated that IL-6 expression 
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was not different between fibre types. These findings lend support to the 
hypothesis that IL-6 is produced in, and released in, muscle tissue but 
does not necessarily confirm that myocytes are a source of IL-6 
production, because the authors could not rule out the possibility that cells 
other than myocytes produced the protein, which then trafficked into the 
muscle cells to perform important functions such as the initiation of a 
stress protein response (Febbraio et al., 2002) and energy metabolism 
(Pedersen et al., 2004a). The aim of the present study is to determine 
whether muscle cells per se are a source of the exercise-induced elevation 
in IL-6 in human skeletal muscle and to characterize the distribution of IL-
6 within and between fibres. An analysis of both IL-6 protein and mRNA 
expression within sectioned muscle biopsy tissue, collected before and 
after contraction, and further characterization of the fibre type and 
glycogen content of each fibre was performed. By simultaneously 
examining the cellular localization of the IL-6 mRNA and protein within 
fibre cross sections, this study would provide further evidence on whether 
muscle cells are indeed a source of IL-6 during contraction. The current 
hypothesis is that IL-6 mRNA and protein would be increased within 
myocytes following exercise and that this would correspond with 
glycogen-depleted fibres. 
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3.2 Materials and Methods 
Subjects and experimental protocol. Seven healthy, active males 
volunteered to participate in this investigation. Subjects signed a written 
consent form after being informed of all procedures and potential risks of 
the study, which was approved by the appropriate Ethics Committee. 
Subjects performed 120 min of continuous cycle ergometry at a power 
output equivalent to ~55% of their individual peak oxygen consumption 
(VO2 peak). The rationale for the exercise bout chosen in this study was 
based on previous data (Febbraio et al., 2004) which demonstrated that 
this mode of exercise would result in appearance of IL-6 in the plasma 
without observable markers of muscle tissue damage or inflammation. 
Muscle biopsies were obtained from vastus lateralis muscle before (PRE) 
and after (POST) exercise using the percutaneous needle method with 
suction under local anesthesia. Immediately following each biopsy, muscle 
tissue was removed from the needle using sterile tweezers and separated 
into two sections: one of these was immediately frozen in liquid nitrogen, 
and one was mounted in TissueTek (Fronine, Riverstone, Australia), frozen 
in isopentane (BDH Laboratory Supplies, Poole, UK) over liquid nitrogen, 
and stored at –80°C until later analysis. 
 
Histological preparation. Multiple 10 µm sections were cut from mounted 
muscle biopsy samples in a cryostat at –20°C. Sections were fixed onto 
gelatin-coated microscope slides by immersion in 5% paraformaldehyde 
(PFA) for 5 min and 70% ethanol for 5 min, air dried, and stored at –80°C 
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until required for analysis. For fibre type analysis, three sections were 
placed on uncoated microscope coverslips and stored at 4°C until 
required.  
 
Immunohistochemical staining for human IL-6 protein. IL-6 protein was 
detected in muscle fibre cross-sections. In brief, sections were washed in 
5% Triton X (Sigma-Aldrich, Castle Hill, Australia) for 10 min and then 
washed twice with 0.02 M phosphate-buffered saline (PBS) and allowed to 
dry. Sections were then blocked overnight with 3% sheep serum (Silenus 
Laboratories, Melbourne, Australia). The next day, sections were washed 
three times in PBS and incubated overnight with a rabbit polyclonal IL-6 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) in a 1:20 dilution in 
1% sheep serum at 4°C. Negative slides were prepared using 1% sheep 
serum in the absence of the primary antibody. The following day, sections 
were washed three times with PBS and labeled with a fluorescein 
conjugated anti-rabbit secondary antibody (Santa Cruz Biotechnology) 
(1:50 dilution in 1% sheep serum) for 2 h at room temperature in the 
dark. After three washes in PBS, sections were air dried and mounted in 
Fluoroguard (Bio-Rad Laboratories, Hercules, CA). Coverslips were sealed 
with clear nail polish and allowed to dry. The IHC methodology described 
above was optimized before sample analysis to provide clear fluorescence 
with minimal nonspecific binding (background). Several concentrations of 
primary antibody were detected by the secondary antibodies fluorescein, 
Texas Red, and biotinylated streptovidin-peroxidase complex. We found 
that detection with Texas Red and biotinylated streptovidin-peroxidase 
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showed consistently high background, suggesting high levels of 
nonspecific binding. Thus, we chose to analyze our samples using 
fluorescein. 
 
Detection and quantitation of IL-6 protein. IL-6 protein was visualized 
using an Olympus BX60 (Olympus Optical Company, Hamburg, Germany) 
fluorescent microscope, and multiple images were captured by a Sensicam 
Imaging camera controlled by Camware software (version 1.21, PCO 
Imaging, Kelheim, Germany). For both positively and negatively stained 
slides, three images were captured on each of three sections. Thus, nine 
sections were captured for each subject at each time point. Fluorescence 
intensity was quantitated using Metamorph software (version 4.6, 
Universal Imaging Corporation, Downingtown, PA). Mean intensity was 
measured on each image, and total mean fluorescence was calculated for 
each sample. To exclude background fluorescence, we subtracted 
quantitated data for the negative slides from the data from positive slides, 
and mean fluorescence was compared between PRE and POST samples. 
 
Comparison of IL-6 fluorescence between glycogen-rich and glycogen-poor 
fibres. Muscle fibre glycogen content was qualitatively assessed on 
sectioned biopsy tissue using Periodic Acid-Schiff Staining (PAS) as 
described previously (Febbraio et al., 1994). This assay is used to 
visualize glycols by producing a magenta stain that is proportional to the 
amount of glycogen in each cross-sectioned muscle fibre. As expected, 
glycogen content was uniformly rich in samples collected before exercise 
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and, therefore, these were not classified. In post-exercise samples, 
however, each fibre was classified as being rich, moderate, or poor in 
glycogen content using a visual scale. To examine whether individual fibre 
glycogen content was associated with IL-6 fluorescence following exercise, 
three glycogen-poor and three glycogen-rich fibres from each section were 
outlined and quantitated. These fibres were matched to their identical 
fibres in the IL-6 IHC-stained sections, and these fibres were quantitated 
using Metamorph software. In essence, we compared IL-6 protein 
between glycogen-rich and glycogen-poor fibres. 
 
Fibre typing. Muscle fibre type was determined in 10 µm sections by one 
of two methods: staining for myofibrillar ATPase activity after reincubation 
with alkaline or acidic buffers, as described elsewhere (Mabuchi and 
Sreter, 1980), which stains type 2 muscle fibres a dark color, or by IHC, 
essentially as described above for IL-6 protein, except that the primary 
antibody used was a mouse anti-slow muscle myosin monoclonal antibody 
(which detects type 1 fibres) (Chemicon International, Temecula, CA) 
diluted 1:500 in 1% sheep serum, and the secondary antibody used was a 
fluorescein conjugated anti-mouse (Santa Cruz Biotechnology) diluted 
1:50 in 1% sheep serum. Sections were washed, air dried, mounted, and 
sealed as described above. We initially used the myofibrillar ATPase 
activity when performing comparisons with IL-6 protein. However, we 
found that this method resulted in shrinkage of the fibres (Figure 3.1), 
making it more difficult to match the sections with the IL-6 protein and 
PAS cross-sections. Hence, when subsequently performing the in situ 
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hybridization analyses, we used the IHC method (Figure 3.4). We suggest, 
therefore, that this method is superior because it does not affect the size 
of the muscle fibres. 
 
In situ hybridization. The IL-6 probe used was derived from a 1.23 kb 
human sequence. The antisense probe for human IL-6 was linearized with 
EcoR1 and labeled using T7 polymerase with 33P-UTP for 2 h at 37°C. The 
probe was hydrolyzed by exposure to alkaline pH for 50 min to produce a 
probe with length of ~0.15 kb. The labelled probe was counted on a 
scintillation counter and diluted in hybridization buffer to a final 
concentration of 40 × 106 dpm•ml–1. In situ hybridization was carried out 
on 10 µm frozen sections of tissue from each of the pre- and post-exercise 
biopsies. Sections were fixed by immersion in buffered 4% 
paraformaldehyde, washed in PBS, and then stored at –20°C after 
dehydration in 70% ethanol. Metastatic breast tissue sections were 
prepared in an identical manner to act as positive controls. Pretreatment 
of sections before hybridization was carried out by microwaving in antigen 
retrieval solution (Citra Plus, BioGenex, San Ramon, CA), followed by 
incubation in pronase E (Sigma, St. Louis, MO) at a concentration of 125 
µg•ml–1 for 10 min at 37°C. Hybridization was carried out overnight in 
hybridization buffer containing 50% formamide at 60°C. Posthybridization 
washes were performed in 50% formamide in 2× SSC at 55°C. In 
addition, unbound probe was removed by incubation of sections in RNase 
A (Sigma, St Louis, MO) at a concentration of 125 µg•ml–1 at 37°C for 1 h. 
Positive signals were detected using Amersham (Little Chalfont 
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Buckinghamshire, UK) LM-1 emulsion and development in Kodak 
(Rochester, NY) Dektol developer, then fixation in Ilford Hypam (Cheshire, 
UK) rapid fixer. Slides were lightly counterstained with hematoxylin and 
viewed using a dark-field condenser. 
Measurement of IL-6 mRNA in muscle biopsies by RT-PCR. Total RNA was 
extracted using the acid phenol method of Chomczynski and Sacchi 
(Chomczynski and Sacchi, 1987) and reverse transcribed using Taqman 
Reverse Transcription Reagents, using random hexamer primers, 
according to the manufacturer’s instructions (Applied Biosystems, Foster 
City, CA). IL-6 mRNA was detected using real-time PCR as described 
previously (Starkie et al., 2001b). For each sample, the IL-6 mRNA 
content was normalized to the housekeeping gene 18S (given a ∆ CT 
value). All samples from a given subject was expressed as fold changes 
relative to the PRE value, which was set to 1, using the ∆∆CT method 
(Applied Biosystems). 
 
Statistical analysis. Paired t-tests were used to detect the effect of 
contraction on quantitated total IL-6 protein (PRE vs. POST), and IL-6 
protein in HIGH and LOW glycogen fibres. P < 0.05 was considered to 
indicate statistical significance. Data are expressed as mean ± SE. 
Statistical analyses were performed using SigmaStat version 2.03 (SPSS, 
Inc., Chicago, IL). 
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3.3 Results 
IL-6 protein is elevated after exercise in skeletal muscle fibres. IL-6 
protein was elevated in muscle biopsy cross-sectional tissue from PRE to 
POST contraction (P < 0.05) that could clearly be observed both within 
and between muscle fibres (Figure 3.1 and 3.2). At PRE, IL-6 protein was 
uniformly expressed across muscle fibres at low levels (Figure 3.1). At 
POST, however, IL-6 protein was expressed in a fibre-specific manner. 
The distribution of IL-6 protein was then examined by quantitatively 
comparing muscle fibres with LOW glycogen content (type 1 fibres) and 
fibres with HIGH glycogen content (type 2 fibres) at POST. This analysis 
revealed that IL-6 protein was expressed predominantly in type 2 muscle 
fibres with HIGH glycogen content (P < 0.05) (Figure 3.3).  
 
IL-6 mRNA is elevated after exercise in skeletal muscle fibres. IL-6 mRNA, 
as measured by real-time RT-PCR, was increased (P < 0.05) 18 ± 8-fold 
when comparing PRE with POST. As can be seen in Figure 3.4, this 
coincided with an increase in IL-6 mRNA, as measured by in situ 
hybridization, within skeletal muscle fibres comparing PRE with POST 
contraction. At PRE, IL-6 mRNA was expressed peripherally at low levels 
around all fibres, and there was a virtual absence of IL-6 in the center of 
the myocytes, suggesting that, at rest, IL-6 in skeletal muscle tissue is 
likely to be located in cell types other than myocytes (Cicco et al., 1990). 
However, at POST, IL-6 mRNA was selectively expressed throughout 
some, but not all, muscle fibres (Figure 3.4). Further examination of these 
44 
fibres showed that type 2 fibres were expressing IL-6 mRNA at a much 
greater level than type 1 fibres and that these fibres also had greater 
glycogen content (Figure 3.4) 
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Figure 3.1 IL-6 protein (left), glycogen content (middle), and fibre type 
(type 2 fibres dark, right) in muscle biopsy sections before (PRE) and after 
(POST) 120 min continuous recumbent cycle ergometry. Yellow circle in 
POST images indicates the same muscle fibre. 
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Figure 3.2 IL-6 protein before (PRE) and after (POST) 120 min 
continuous recumbent cycle ergometry. #Difference between PRE and 
POST (P < 0.05). Values are expressed as mean ± SE. 
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Figure 3.3 IL-6 protein in type 1 (low glycogen content) and type 2 (high 
glycogen content) fibres after (POST) 120 min continuous recumbent cycle 
ergometry. #Difference between PRE and POST (P < 0.05). Values are 
expressed as mean ± SE. 
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Figure 3.4 IL-6 mRNA (left), glycogen content (middle), and fibre type 
(type 1 fibres light, right) in muscle biopsy sections before (PRE) and after 
(POST) 120 min continuous recumbent cycle ergometry. Human 
metastatic breast tissue was used as a positive control (bottom). Yellow 
circle in the POST images indicates the same muscle fibre. 
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3.4 Discussion 
This is the first study to identify that IL-6 is produced within muscle cells 
during muscular contraction. In a recent study by Penkowa et al. (2003), 
IL-6 protein was detected within muscle fibres and shown to increase 
following acute contraction. Although this study showed that IL-6 protein 
was indeed increased in muscle cells, the authors did not measure the 
cellular localization of IL-6 mRNA. Therefore, while providing a good 
indication that myocytes were a source of IL-6 during contraction, this 
previous study could not rule out the possibility that IL-6 may have been 
produced by other cell types before being trafficked into the muscle cell to 
perform intracellular functions. By using in situ hybridization to determine 
the cellular localization of IL-6, coupled with the quantitatively analyzed 
IL-6 protein within muscle fibres using IHC detection, our data provide the 
first solid evidence that human skeletal myocytes indeed produce IL-6 in 
response to contraction.  
 
Our IL-6 protein data differ somewhat from that reported by Penkowa et 
al. (2003), who showed that IL-6 protein was distributed homogenously 
across each muscle fibre and did not appear to vary between fibre types. 
In contrast, the distribution of IL-6 protein after contraction in the current 
study could clearly be detected in predominantly type 2 fibres. It is 
difficult to identify the cause of this disparity between studies, given that 
both studies used a prolonged concentric model of contraction and the 
sampling methodologies of each study were similar. However, as reported 
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in our methods, our optimization for IHC not only included fluorescein as a 
secondary antibody, but also biotinylated streptovidin-peroxidase and 
Texas Red tagged secondary antibodies. We found that these two latter 
antibodies were less effective than fluorescein in eliminating background 
expression, and it is possible that the difference when comparing the 
results from the study of Penkowa et al. with the present study was the 
choice of the secondary antibody. Irrespective of why our data differ with 
those of Penkowa et al., we are confident that our protein data are an 
accurate representation of the fibre distribution of IL-6 because they are 
very consistent with our in situ hybridization data. 
 
Our data reporting that IL-6 protein and mRNA expression was located in 
predominantly type 2 fibres with high glycogen content after contraction is 
an important novel finding. This finding was very surprising to us, and 
contrary to our hypothesis, which was based on the consistent finding 
from previous studies that IL-6 mRNA expression and protein release is 
exacerbated with glycogen depletion (Keller et al., 2001b; Steensberg et 
al., 2001b). However, it is well known that during prolonged steady-state 
cycling, muscle glycogenolysis occurs predominantly in type 1 fibres, and 
glycogenolysis in the type 2 fibres only occurs when type 1 fibres are 
glycogen depleted (Gollnick et al., 1973). Given our data that IL-6 protein 
and mRNA are present in predominantly type 2 fibres, we propose that an 
augmented increase in IL-6 mRNA and protein release is evident with low 
pre-exercise glycogen content because type 1 fibres become glycogen 
depleted earlier, resulting in the earlier recruitment of type 2 fibres. 
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In conclusion, our data clearly demonstrate that human skeletal myocytes 
per se are a source of contraction induced IL-6 and that was IL-6 is 
predominantly located in type 2 muscle fibres. 
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CHAPTER FOUR 
 
 
 
CYTOKINE GENE EXPRESSION IN HUMAN 
SKELETAL MUSCLE DURING CONCENTRIC 
CONTRACTION: EVIDENCE THAT IL-8, LIKE IL-6, 
IS INFLUENCED BY GLYCOGEN AVAILABILITY  
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4.1 Introduction 
 
Cytokines are pleiotropic proteins produced by virtually every nucleated 
cell in the body (Tilg, 2001). However, in most tissues including skeletal 
muscle, the constitutive expression of these cytokines is either minimal or 
absent (Frost et al., 2002). Rather, the expression of cytokines is induced 
by a myriad of physiological, pathological or chemical stimuli. Recently, 
Frost et al. (2002) demonstrated that lipopolysaccharide (LPS) induced 
the gene expression of a number of cytokines, namely interleukin (IL)-6, 
tumour necrosis factor (TNF)-α, IL-12, IL-1α, IL-1ra and TNF-β in mouse 
skeletal muscle. In addition, it was also demonstrated that 3 hours of 
running exercise, which would result in some tissue damage, induced the 
mRNA expression of IL-1β, IL-6, IL-8, IL-10 and TNF-α in human skeletal 
muscle (Nieman et al., 2003). These results were not surprising, because 
LPS is a potent stimulus for cytokine production in a variety of cell types 
including blood mononuclear cells, whereas tissue damage will result in 
neutrophil and macrophage infiltration into skeletal muscle (McLoughlin et 
al., 2003) which are known to produce a variety cytokines (Akira et al., 
1993). Work from our group has focused on the effect of “non-damaging” 
muscle contraction on the induction of cytokines within skeletal muscle. It 
has been demonstrated that muscle contraction, in the absence of 
markers of muscle damage, rapidly increases IL-6 mRNA expression in 
skeletal muscle biopsy samples (Starkie et al., 2001b; Steensberg et al., 
2001b; Steensberg et al., 2002; Steensberg et al., 2000b), whereas the 
intramuscular nuclear transcriptional activity of IL-6 is rapidly increased 
with the onset of such exercise (Keller et al., 2001b). Of note, however, is 
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the observation that unlike LPS, this type of muscle contraction does not 
increase IL-6 mRNA (Ullum et al., 1994) or protein (Starkie et al., 2000b; 
Starkie et al., 2001c) expression in blood mononuclear cells. This has lead 
us to hypothesize that the contraction induced IL-6 expression in skeletal 
muscle is not a consequence of trauma or damage, but rather is a specific 
biochemical phenomenon to allow the muscle to release this cytokine to 
mobilize substrate from fuel depots within the body to facilitate energy 
metabolism (Febbraio and Pedersen, 2002). To this end, IL-6 protein is 
released from skeletal muscle during prolonged knee extensor or bicycle 
exercise (Steensberg et al., 2001b; Steensberg et al., 2002; Steensberg 
et al., 2000b) and its release is further elevated when intramuscular 
glycogen stores are low (Steensberg et al., 2001b) or attenuated when 
glucose availability is increased (Febbraio et al., 2003b). In addition, it 
appears that IL-6 acts in a “hormone like” manner to increase lipolysis 
and fat oxidation (van Hall et al., 2003). 
 
In contrast to the observations of contraction-induced skeletal muscle 
release of IL-6 and the data obtained after 3 hours of treadmill running 
(Nieman et al., 2003), concentric muscle contractions do not increase 
TNF-α  gene expression in contracting skeletal muscle (Steensberg et al., 
2002). In addition, chronic muscular activity down-regulates TNF-α gene 
expression in the skeletal muscles of elderly humans (Greiwe et al., 
2001). The failure for such muscular contraction to induce TNF-α gene 
expression in skeletal muscle is not surprising given the marked increase 
in glucose uptake during exercise and the well described negative effect of 
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TNF-α on glucose disposal (Febbraio and Pedersen, 2002). Whether 
muscle contractions per se increase the expression of other cytokines 
within skeletal muscle or whether carbohydrate availability mediates such 
expression is not known and this was the aim of the present study. We 
chose to study humans during short-term cycling exercise to minimize any 
possibility of muscle damage inducing a local inflammatory response. We 
hypothesised that muscle contraction would not result in the ubiquitous 
induction of cytokine genes. Rather, we hypothesized that IL-6 would be 
the only cytokine markedly increasing its mRNA expression in response to 
contraction or glycogen availability, because of its specific “endocrine-like” 
role that has been identified.  
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4.2 Materials and Methods  
Subjects and experimental protocol. Eight active, but not specifically 
trained, males (24 ± 2 yr, 77 ± 3kg, and 181 ± 2 cm) participated in the 
study, which was approved by the Royal Melbourne Institute of 
Technology (RMIT) University Human Ethics Committee. Written informed 
consent was obtained from all human subjects. Each visited the laboratory 
and performed an incremental exercise test on a cycle ergometer (Lode, 
Excalibur, Groningen, The Netherlands) until they reached volitional 
exhaustion. The peak pulmonary oxygen uptake (VO2peak) averaged 49.0 
± 3.2 ml•kg-1•min-1. Expired pulmonary gases (Quark b2, COSMED, Rome, 
Italy) were collected and analyzed online to compute VO2peak. 
 
The subjects subsequently visited the laboratory for two experimental 
trials separated by at least 1 week and conducted in random and 
counterbalanced order. During these trials they attended the laboratory 
between 1600 and 1700 to perform glycogen-depleting exercise and 
returned the following morning at ~0800 to perform the experimental 
trial. The glycogen-depleting exercise involved two exercise bouts 
consisting of continuous cycling at 70% VO2peak for 20 minutes followed 
by 20 minutes intermittent exercise. The intermittent exercise consisted of 
2 min cycling at 90% VO2peak followed by 2 min at 50% VO2peak. 
Subjects then performed ~20 minutes arm-cranking exercise (~50 W) to 
deplete glycogen of the upper arms. After resting for 5 minutes, the 
aforementioned cycling protocol was repeated until subjects reached 
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volitional exhaustion. Five all-out sprints were then performed for 30 
seconds with a 2 minutes recovery period. The duration of the glycogen-
depleting exercise was ~2.5 hours (average of 92 ± 3 minutes cycling 
exercise). Water intake was permitted throughout all trials, and no 
adverse events were reported by subjects. Subjects were provided with an 
overnight food parcel. On one occasion, the 6.2 MJ diet consisted of 79% 
carbohydrate, 3% fat, and 18% protein (denoted herein as Con); 
whereas, on the other visit, the 6.4 MJ diet consisted of 4% carbohydrate, 
59% fat, and 37% protein (denoted herein as Lo Gly). Subjects were 
instructed to consume all food before 2200 and were permitted to 
consume water thereafter. Subjects arrived at the laboratory the following 
morning after an overnight fast. They voided, lay supine on a bed, and a 
Teflon catheter was inserted into an antecubital vein for blood sampling. 
One leg was prepared for subsequent needle biopsy by making two 
incisions through the skin and fascia of the vastus lateralis under local 
anesthesia. Immediately before exercise, a muscle sample was obtained 
by needle biopsy. The leg was bandaged and the subject moved to the 
cycle ergometer and commenced cycling at ~70% VO2peak. Venous blood 
samples were obtained at 20 minutes intervals during exercise. In 
addition, expired pulmonary gases (Quark b2, COSMED) were collected 
and analyzed online at 20 minutes intervals during exercise. A second 
muscle sample was obtained from the second incision immediately after 
the cessation of exercise (at 60 minutes) with the subject on the cycle 
ergometer. Muscle samples were obtained from the contralateral leg in the 
subsequent trial. 
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Muscle Tissue Analyses 
Muscle glycogen. A portion of muscle (~10 mg) was freeze-dried, 
dissected free of any blood and connective tissue, powdered, and analyzed 
for glycogen as previously described (Febbraio et al., 2003b).  
 
Measurement of mRNA expression. A portion of muscle (~30 mg) was 
extracted for total RNA using a modification of the acid guanidium 
thiocyanate-phenol chloroform extraction method of Chomczynskiand 
Sacchi (Chomczynski and Sacchi, 1987) described elsewhere (Febbraio 
and Koukoulas, 2000). The total RNA was quantified two to three times 
before 1 ng of each total RNA sample was reverse transcribed in a 10 µl 
reaction containing 1 Χ TaqMan RT buffer, 5.5 mM MgCl2, 500 mM each 
2’-deoxynucleoside 5’-triphosphate, 2.5 mM random hexamers, 0.4 U•ml-1 
RNase inhibitor, 1.25 U•ml-1 Multiscribe Reverse Transcriptase (Applied 
Biosystems, Foster City, CA) and made up to volume with milli-Q H2O 
(0.05% DEPC treated). Control samples were also analyzed where all the 
above reagents are added to RNA samples except the Multiscribe Reverse 
Transcriptase. The reverse transcription reactions were performed using a 
GeneAmp PCR system 2400 (Perkin, Elmer, Wellesley, MA) with conditions 
at 25°C for 10 minutes, 48°C for 30 minutes and 95°C for 5 minutes. 
EDTA (2 ml 0.5 M; pH 8.0) was added to each sample and stored at -20°C 
until further analysis. 
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Real-time PCR was employed to quantitate human IL-1α, IL-1β, IL-2, IL-4, 
IL-5, IL-6, IL-8, IL-10, the p35 and p40 subunits of IL-12 (IL-12p35, IL-
12 p40), IL-15, interferon (IFN)-γ, and TNF-α. All cytokines except IL-6 
were analyzed using the Taqman Human Cytokine Gene Expression Plate 
(Applied Biosystems, Foster City, CA). Human probe and primers for IL-6 
were designed (Primer Express version 1.0 Applied Biosystems) from the 
human gene sequence accessed from GenBank/EMBL as previously 
described (Starkie et al., 2001b). For all genes, a TaqMan probe was 
labeled with the fluorescent tags FAM (6-carboxyfluorescein) at the 5’ end 
and TAMRA (6-carboxy-tetramethylrhodamine) at the 3’ end and 
ribosomal 18S mRNA was also amplified as our reference gene. We 
quantitated gene expression using a multiplex comparative critical 
threshold (CT) method (Bio-Rad i Cycler IQ, Hercules, CA). 
 
PCR reactions were carried out in duplicate in 50 µl reactions of TaqMan 
universal PCR master mix (1 Χ), 50 nM TaqMan 18S probe, 20 nM 18S 
forward primer, 80 nM 18S reverse primer, and probes and primers at 
specific concentrations. Twenty nanograms of cDNA were amplified using 
the following conditions: 50°C for 2 min, 95°C for 10 minutes followed by 
50 cycles of 95°C for 15 seconds and 60°C for 1 minute. Of note, in 
previous experiments where we have followed these procedures, we 
compared our gene expression data obtained from real-time PCR 
methodology with that obtained using a Northern blot and have 
demonstrated comparable results (Steensberg et al., 2001b). For each 
sample, 18S CT values were subtracted from the gene of interest CT values 
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to derive a ∆CT value. The resting value for each subject during each trial 
was then subtracted from the exercise samples for each subject to derive 
a ∆∆CT value. The expression of the genes of interest relative to the 
resting samples was then evaluated using the expression 2-∆∆CT. The 
coefficient of variation, determined on the CT value of the 18S samples, 
was less than 1%. 
 
Blood analyses. Blood for plasma glucose analysis was collected into a 
tube containing fluoride EDTA, mixed, and spun in a centrifuge at 2200 g 
for 8 minutes at 0°C. The plasma was later analyzed for glucose using an 
automated glucose/lactate analyzer (YSI 2300 STAT PLUS, Yellow Springs, 
OH). Blood samples for plasma IL-6 and IL-8 concentration were drawn 
into glass tubes containing EDTA. The tubes were spun immediately at 
2,200 g for 15 minutes at 4°C and the plasma was stored at -80°C until 
analyses were performed. ELISA kits (R&D Systems, Minneapolis, MN), 
were used to quantify plasma IL-6 and IL-8, which were quantified using 
chemiluminescence. Plasma creatine kinase (CK) was determined by 
automated enzyme reactions using the International Federation of Clinical 
Chemistry recommended method (automated analyses for AU5000, 
Olympus, Tokyo, Japan).  
 
Histological determination of muscle fibre cross sections. In the present 
study we did not freeze clamp muscle in isopentane for histological 
determination. To provide further evidence that bicycle exercise does not 
induce muscle damage, we collected muscle samples prepared for 
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histochemical determination from a separate cohort of subjects who 
exercised for a similar duration and intensity on a bicycle ergometer. It is 
standard practice in our laboratory to perform the glycogen depletion 
protocol before experimentation to minimize any differences in pre-
exercise glycogen content between subjects. Consequently, the subjects 
in this cohort also performed the same glycogen depletion protocol before 
being provided with the identical diet that was given to subjects in Con. 
Muscle samples obtained before and after exercise were rapidly frozen in 
isopentane, subsequently sectioned frozen in a cryostat (10 µm sections) 
and stained with hematoxylin and eosin. 
 
Statistical analysis. Analysis of the IL-6 and IL-8 mRNA measures revealed 
that the data were not normally distributed. To ensure homogeneity of the 
data, data were log transformed before statistical analysis. All other 
parameters were normally distributed. A two-way (trial Χ time) ANOVA 
with repeated measures on the time factor was used to compute the 
statistics (Statistica, Tulsa, OK), with significance accepted with a P value 
of < 0.05. If analyses revealed a significant interaction, a Newman Keuls 
post hoc test was used to locate specific differences. Data are presented 
as means ± SE. 
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4.3 Results  
Workload and pulmonary measures. Subjects cycled at an average of 174 
± 12 W during the experimental trials. Although mean VO2peak did not 
differ when comparing trials (34.7 ± 2.2 versus 34.2 ± 2.2 ml•kg-1•min-1) 
for Con and Lo Gly, respectively), respiratory exchange ratio was higher 
(P < 0.05) in Con (0.90 ± 0.01) compared with Lo Gly (0.81 ± 0.01). 
 
mRNA abundance of cytokines. The pattern of cytokine gene expression is 
presented in Table 4.1. Of the 13 cytokines analyzed, 5 were detected in 
the muscle biopsy samples. These were IL-1β, IL-6, IL-8, IL-15, and TNF-
α. Only IL-6 and IL-8 were induced (P < 0.05) by contraction. In addition, 
the contraction-induced expression of these cytokines was augmented (P 
< 0.05) during Lo Gly (Figure 4.1). 
 
Muscle glycogen and plasma glucose. Resting muscle glycogen was higher 
(P < 0.05) in Con compared with Lo Gly (375 ± 35 versus 163 ± 27 mmol 
glycosyl units•kg-1 dry mass for Con and Lo Gly, respectively) and was 
reduced (P < 0.05) to 102 ± 32 versus 17 ± 5 mmol glycosyl units•kg-1 
dry mass for Con and Lo Gly, respectively (Figure 4.2). Plasma glucose 
was not different when comparing trials at rest, and whereas plasma 
glucose concentration was maintained in Con, it fell (P < 0.05) in Lo Gly 
such that the values at 40 and 60 minutes were lower (P < 0.05) in Lo Gly 
compared with Con (Figure 4.2). 
 
63 
Plasma cytokines and creatine kinase. Plasma IL-6 was not different at 
rest when comparing trials. Plasma IL-6 increased (P < 0.05) after 40 
minutes in both trials, but the increase was greater at 40 and 60 minutes 
in Lo Gly such that the concentrations at these times were higher (P < 
0.05) compared with Con (Figure 4.3). In contrast, IL-8 was not different 
at rest or at any point during exercise when comparing Con with Lo Gly, 
and exercise per se did not increase plasma IL-8 in either trial (Figure 
4.3). Plasma creatine kinase (CK) was not different at rest when 
comparing trials and was not increased when comparing values at 60 
minutes with those at rest (Table 4.2).  
 
Histological determination of muscle fibre cross sections. We were unable 
to detect any differences in the general histological architecture of the 
muscle cross sections before and after exercise. Pre- and post-exercise 
cross sections from a single subject are displayed in Figure 4.4. 
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Table 4.1 Pattern of cytokine expression in skeletal muscle. The 
expression of interleukin (IL)1-β, IL-6, IL-8, IL-15, and tumour necrosis 
factor (TNF)-α were detected in the pre-exercise muscle biopsy samples. 
Of these only IL-6 and IL-8 mRNA were contraction inducible, and their 
increase were exacerbated in the presence of low intramuscular glycogen. 
 
 
 
 
Cytokine Basal Expression 
Concentric 
Contraction 
Inducible? 
Influenced by 
Glycogen 
Content? 
IL-1α No No No 
IL-1β Yes No No 
IL-2 No No No 
IL-4 No No No 
IL-5 No No No 
IL-6 Yes Yes Yes 
IL-8 Yes Yes Yes 
IL-10 No No No 
IL-12p35 No No No 
IL-12p40 No No No 
IL-15 Yes No No 
IFN-γ No No No 
TNF-α Yes No No 
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Figure 4.1 Contraction-induced increase in interleukin (IL)-6 (A) and IL-8 
(B) mRNA during exercise with normal (Con) or low (Lo Gly) pre-exercise 
intramuscular glycogen content. Values are expressed as a fold change 
from rest with rest equal to 1 arbitrary unit (means ± SE). * Difference (P 
< 0.05) compared with Con; n = 8.    
 
A 
B 
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Figure 4.2 Muscle glycogen (A) and plasma glucose (B) concentrations 
during exercise with normal (   ) or low (   ) pre-exercise intramuscular 
glycogen.* Difference (P < 0.05) compared with 0 min. Values are 
expressed as mean ± SE; n = 8. 
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Figure 4.3 Plasma IL-6 (A) and IL-8 (B) concentrations during exercise 
with normal (   ) or low (   ) pre-exercise intramuscular glycogen content. 
* Difference (P < 0.05) compared with Con. Values are expressed as 
mean ± SE; n = 8. 
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Table 4.2 Plasma creatine kinase concentrations before (0 minute) and 
after (60 minutes) 1 hour of cycling exercise with either Con or Lo Gly 
intramuscular glycogen availability. Values expressed in U•L-1 as means ± 
SE (n = 8). Con, normal; Lo Gly, reduced. 
 
 
Con  Lo Gly 
0 min 60 min  0 min 60 min 
343 ± 60 353 ± 69  291 ± 88 294 ± 84 
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Figure 4.4 Muscle cross section from the vastus lateralis muscle taken 
from an individual before (A) and after (B) cycling exercise performed at 
70% peak pulmonary oxygen uptake (VO2peak) for 60 minutes. Greyscale 
images were stained for hematoxylin and eosin.  
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4.4 Discussion  
The results from this study demonstrate that cytokines are not 
ubiquitously expressed in skeletal muscle and the mRNA abundance of IL-
6 and IL-8 alone appear to be increased by the type of exercise used in 
this study. Because the mode of exercise used in the present study did not 
induce observable markers of muscle tissue damage or inflammation and 
because the contraction-induced increase in IL-8 and IL-6 was potentiated 
when glycogen availability was reduced, our data suggest that the mRNA 
abundance for these two cytokines is influenced by metabolic processes 
rather than inflammation secondary to muscle damage.  
 
In the present study we only measured the mRNA abundance and not the 
rate of gene transcription. Therefore, our measures may reflect an 
increase in gene transcription and/or increases in mRNA stability or, 
indeed, a combination of both. Although we have no evidence regarding 
the contraction induced rate of transcription for IL-8, however, Keller et 
al. (2001b) demonstrated that the rate of IL-6 gene transcription closely 
matches the mRNA abundance during exercise with regardless of the pre-
exercise glycogen levels. In this respect we are confident, at least for our 
IL-6 measures, that our results reflect the rate of gene transcription. It is 
well known that skeletal muscle not only contains myocytes, but also 
smooth muscle cells, fibroblasts, endothelial cells, and macrophages, and 
these cells are also known to produce IL-6 (Cicco et al., 1990; De Rossi et 
al., 2000; Klouche et al., 1999; Podor et al., 1989). Because we only 
obtained muscle biopsy samples, it was possible that the elevations seen 
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in IL-6 and IL-8 mRNA expression may have been due to an increased 
mRNA expression in cells other than skeletal myocytes. We have not 
examined mRNA localization of IL-8 in muscle cells; however, our in situ 
hybridization data, presented in the previous chapter, have clearly 
demonstrated that the mRNA abundance of IL-6 increases within the 
skeletal muscle cells after contraction, and the quantification of mRNA 
abundance using this method matches the rate seen using RT-PCR in 
muscle biopsy homogenates. 
 
The results from the present study differ somewhat with those that have 
stimulated muscle with LPS (Frost et al., 2002) or muscle contraction with 
a large eccentric component (Nieman et al., 2003). In particular, whereby 
these two stimuli resulted in a marked increase in the mRNA abundance of 
TNF-α and IL-1β, our data showed no such effect, although both TNF-α 
and IL-1β were basally expressed in our tissue samples. The current 
findings are consistent with the previous observations in humans during 
knee extensor exercise (Steensberg et al., 2002), which has also been 
shown to result in minimal muscle damage (Steensberg et al., 2000b). It 
is well known that TNF-α is expressed in response to tissue damage and 
inflammation (Broussard et al., 2003). In addition, Fielding et al. (1993) 
demonstrated that ultrastructural damage to skeletal muscle is associated 
with neutrophil infiltration and IL-1β accumulation. In the previous study 
reported by Nieman et al. (Nieman et al., 2003), the exercise-induced 
increase in TNF-α and IL-1β was not affected by carbohydrate availability, 
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providing further evidence that the observed increases were probably due 
to inflammatory and not metabolic processes. 
 
Although our data cannot categorically rule out the presence of some 
muscle damage, the evidence strongly argues against such an occurrence. 
Firstly, as discussed, we saw no evidence that either TNF-α and IL-1β 
were increased by contraction, and these cytokines are often, if not 
always, elevated when muscle damage occurs (Fielding et al., 1993; Frost 
et al., 2002; Nieman et al., 2003). Secondly, although the resting plasma 
creatine kinase (CK) levels were in the high range of normal, there was no 
indication that CK rose during 60 minutes of exercise. This is in contrast 
with previous studies where subjects ran (Walsh et al., 2001) or 
performed eccentric cycling (Toft et al., 2002) for 60 minutes. In these 
studies, where exercise involved an eccentric component, a marked 
increase in plasma CK was observed after 60 minutes. Thirdly, our 
previous data have demonstrated that this mode of exercise results in 
intramyocellular increases in both IL-6 mRNA and protein but does not 
increase IL-6 mRNA in the area surrounding the fibres (Chapter 3). 
Finally, despite our histological data are from a separate cohort of 
subjects, these subjects nonetheless underwent a similar exercise 
regimen, including exercise the previous day. The histology did not 
provide any evidence of ultrastructural damage. Our data, therefore, 
suggest that there is no observable muscle damage during short-term (60 
minutes) continuous exercise. 
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Our observations that IL-6 increased with non-contracting skeletal muscle 
and that the increase was augmented when intramuscular glycogen levels 
were low are entirely consistent with previous studies that have examined 
this relationship (Keller et al., 2001b; Steensberg et al., 2001b). Although 
in the present study we did not sample for leg IL-6 release, the fact that 
leg IL-6 release can account for much of the plasma IL-6 accumulation 
(Steensberg et al., 2000b), suggests that our plasma IL-6 data suggest 
that, like previous studies (Steensberg et al., 2001b), circulating IL-6 
appears to be related to glycogen availability. Recently, however, using in 
situ hybridization and immunohistochemical techniques, we identified that 
IL-6 is produced almost exclusively by type 2 muscle fibres. Given that 
type 1 fibres are recruited during prolonged contraction, we showed that 
IL-6 was inversely related to glycogen content within muscle fibres 
(Chapter 3). Although these recent results seem somewhat contradictory 
to the present and previous findings (Keller et al., 2001b; Steensberg et 
al., 2001b), there is a viable explanation for the apparent anomaly. In the 
present and previous studies (Keller et al., 2001b; Steensberg et al., 
2001b), muscle glycogen levels were analysed from mixed fibre muscle 
biopsies and patterns of glycogen depletion within specific fibre types were 
not obtained. It is likely, however, that as type 1 fibres became depleted 
of muscle glycogen, type 2 fibres were subsequently recruited, producing 
and then releasing IL-6. 
 
A key finding from this study was that like IL-6, IL-8 mRNA is induced by 
concentric muscle contraction and that its induction is markedly 
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exacerbated by low intramuscular glycogen stores. It must be noted, 
however, that where the increase of IL-6 was ~150-fold in Lo Gly, the 
increase in IL-8 was ~40-fold (Figure 4.1). In addition, whereas IL-6 
increased in the circulation in both trials, but to a greater extent in Lo Gly, 
no such increase in IL-8 was observed. Hence, there appear to be 
differences in the biological profile of contraction-induced increases in 
these two cytokines. IL-8 has been shown to increase in skeletal muscle, 
but is blunted by carbohydrate ingestion throughout exercise (Nieman et 
al., 2003). However, the biological significance of this increase was not 
discussed in this previous paper (Nieman et al., 2003) and little is known 
regarding the significance of the increase in skeletal muscle IL-8 mRNA. 
IL-8 was identified over a decade ago (Baggiolini and Clark-Lewis, 1992) 
and is classed as one of 40 chemotactic peptides ranging from 8 to 14 
kDa. In this respect, the biological action and size of IL-8 are quite 
different compared with IL-6. In recent years, biological roles have been 
identified for muscle-derived IL-6, both as an intramyocellular signal for 
heat shock proteins (Febbraio et al., 2002) and as an endocrine-like 
molecule to be released from the muscle to module metabolic processes 
such as lipolysis (Febbraio and Pedersen, 2002; van Hall et al., 2003). In 
the current study, we saw no evidence that IL-8 was released into the 
circulation, so in this respect, it is unlikely to have significant circulatory 
actions. Whereas it is possible that IL-8 has some biological role to play in 
the etiology of muscle metabolism, it is also possible that its induction is 
simply a consequence of a disruption to myocellular homeostasis. In most 
cell types IL-8 is markedly induced via the mitogen activated protein 
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kinase (MAPK) pathways. In particular, p38 appears to be a potent 
upstream signalling molecule for IL-8 in monocytes, neutrophils, and 
smooth muscle cells (Hoffmann et al., 2002).  
 
In summary, our data demonstrate that cytokines are not ubiquitously 
expressed in skeletal muscle and that IL-8, like IL-6, is influenced by the 
glycogen availability within the contracting muscle. The biological role of 
IL-8 during exercise is yet to be elucidated. 
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CHAPTER FIVE 
 
 
 
 
ALTERING DIETARY NUTRIENT INTAKE THAT 
REDUCES GLYCOGEN CONTENT LEADS TO 
PHOSPHORYLATION OF NUCLEAR p38 MAPK IN 
HUMAN SKELETAL MUSCLE 
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5.1 Introduction 
As discussed, interleukin (IL-6) is a pleiotropic cytokine produced by a 
variety of tissues during inflammation arising from a variety of 
pathophysiological conditions (Pinsky et al., 1993; Strassmann et al., 
1992; Ullum et al., 1996). As discussed in Chapter 4, skeletal muscle cells 
are also capable of producing IL-6 in response to various chemical stimuli 
such as incubation with lipopolysaccharide (LPS) (Frost et al., 2002; Frost 
et al., 2003), reactive oxygen species (ROS) (Kosmidou et al., 2002) and 
inflammatory cytokines (Frost et al., 2003; Luo et al., 2003). In these 
circumstances, the upstream signalling events that lead to the induction of 
IL-6 have been well categorized. Both LPS and inflammatory cytokines 
such as IL-1β and TNF-α can activate IL-6 via the mitogen-activated 
protein kinases (MAPK) c-jun terminal kinase (JNK) (Frost et al., 2003), 
p38 MAPK (Luo et al., 2003), and the transcription factors nuclear factor 
kappa-β (NFκβ) and activator protein-1 (AP1) (Kosmidou et al., 2002). 
These signalling events that lead to IL-6 production in cultured skeletal 
muscle cells are consistent with experiments conducted in cardiac 
myocytes (Craig et al., 2000) and monocytes (Tuyt et al., 1999). 
However, no studies have examined upstream IL-6 signalling in skeletal 
muscle in vivo. 
 
As discussed in Chapter 1, human skeletal muscle appears unique in that 
it can produce IL-6 during contraction in the absence of observable 
markers of inflammation (Febbraio and Pedersen, 2002), linking IL-6 to 
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metabolism rather than inflammation. Penkowa and colleagues (2003) 
have used immunohistochemical techniques to demonstrate that the 
contraction-induced increase in IL-6 protein formation occurs within the 
muscle cells, a finding that was confirmed by measuring 
immunohistochemical detection of IL-6 protein and in situ hybridization 
determination of IL-6 mRNA by our group (Chapter 3). In both of these 
previous experiments, the mode of contraction was prolonged and 
concentric, and markers of damage were absent. During this type of 
exercise, the rate of IL-6 gene transcription within human skeletal muscle 
is rapid (Keller et al., 2001b) and it has been previously hypothesized that 
this is due to calcium (Ca2+) being released from the lateral sacs of the 
sarcoplasmic reticulum to activate IL-6 through activation of nuclear factor 
of activated T cells (NFAT) (Febbraio and Pedersen, 2002). Previous 
studies in B lymphocytes have demonstrated that the activation of NFAT 
was induced by a low sustained [Ca2+]i (Dolmetsch et al., 1998), which is 
characteristic of prolonged skeletal muscle contractile activity. NFAT is 
present in ~10-fold higher concentrations in neuronal and muscle cells 
when compared with other cell types (Olson and Williams, 2000b). When 
activated, calcineurin binds to and dephosphorylates NFAT, allowing it to 
translocate to the nucleus where it associates with other transcription 
factors (Olson and Williams, 2000b). 
 
Although muscle contraction induces IL-6 gene transcription in skeletal 
muscle, it is also clear that this effect is exacerbated in the presence of 
low intramuscular glycogen stores as we showed in Chapter 4 and others 
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have shown previously (Keller et al., 2001b; Steensberg et al., 2001b). 
Despite these observations, the signalling events that mediate these 
processes are not well understood. It is, however, well known that p38 
MAPK often (Boppart et al., 2000b; Goodyear et al., 1996b) but not 
always (Williamson et al., 2003b) increases in skeletal muscle during 
contraction. To date, no studies have determined whether glycogen 
availability influences the expression of p38 MAPK in contracting skeletal 
muscle. However, since p38 MAPK is a stress-activated protein kinase and 
low glycogen decreases the energy availability in contracting muscle, this 
hypothesis is plausible. 
 
Based on the previous studies in skeletal muscle cell culture experiments 
and other cell/tissue types, a model was recently proposed which 
hypothesized that contraction could activate IL-6 transcription through 
activation of NFAT, and that low glycogen would activate p38 MAPK 
leading to a potentiation of IL-6 transcription and protein production 
(Febbraio and Pedersen, 2002). In the present study, we tested the 
hypothesis that the transcription of IL-6 during predominantly concentric 
exercise was activated by NFAT, but enhanced with low glycogen due to 
increased nuclear localization and phosphorylation of p38 MAPK. To do 
this, we isolated nuclear fractions of muscle samples before and after 
exercise and probed them for total protein or phosphorylated proteins 
using Western blot analyses. 
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5.2 Materials and Methods  
Human Experiments 
The present experiments were performed on muscle samples obtained 
from our human study described in Chapter 4. Con and LCHO denote 
control and low carbohydrate trials, respectively.  
 
Muscle tissue analyses 
Measurement of mRNA expression. The measurement of IL-6 mRNA was 
as described in Chapter 4. 
 
Extraction of nuclear proteins. Nuclear proteins were extracted from the 
muscle samples using a technique described previously (McGee et al., 
2003). Briefly 30 mg of the muscle was homogenized in 500 mL of 
prechilled Buffer A (250 mM, sucrose, 10mM Tris pH 7.5, 10 mM NaCl, 3 
mM MgCl2, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride 
(PMSF), and 2 ml per 30 mg tissue protease inhibitor cocktail). The 
homogenate was spun at 500 g for 5 minutes at 4°C. The supernatant 
containing cytosolic materials (crude fraction) was removed and stored at 
-80°C until required. Then 500 ml of prechilled Buffer B (50 mM Tris pH 
7.5, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 50 mM 
MgCl2, 50 mM NaF, 5 mM Na pyrophosphate, 1 mM DTT, 1 mM PMSF, 2 
ml per 30 mg tissue protease inhibitor cocktail) was added to resuspend 
the remaining pellet. After 10 minutes incubation on ice with occasional 
mixing, the pellet mixture was then spun for 5 minutes at 3000 g at 4°C. 
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The supernatant representing the nuclear fraction was extracted and 
stored at -80°C until required. Fraction purity was assessed by Western 
blotting on Histone H1 as described previously (McGee et al., 2003). 
 
Western blotting. SDS-PAGE was used to separate and identify proteins 
from the two fractions (nuclear and cytosolic). Thirty micrograms of 
protein from each sample was transferred by electrophoresis on 10% SDS 
polyacrylamide gel at 130 V. The separated proteins were then transferred 
using a semidry transfer on to a nitrocellulose membrane and incubated in 
blocking buffer [5% skim milk powder in Tris-buffered saline with 0.25% 
Tween (TBST)] for 1 h. After an overnight exposure to primary antibodies 
against total and phosphorylated p38 MAPK, total and phosphorylated 
JNK, NFκB (Cell Signalling Technology, Inc., Beverly, MA), or NFAT (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) (1 in 1000 in blocking buffer) at 
4°C, the membrane was then subjected to anti-rabbit horseradish 
peroxidase-conjugated secondary antibodies (1 in 10,000 in blocking 
buffer) for 1 h. After 30 minutes of washing, antibody binding was 
detected by enhanced chemiluminescence substrate (Pierce SuperSignal 
chemiluminescent; Pierce, Rockford, IL) and a Kodak Image Station 
440CF (NEN Life Science Product, Boston, MA). Band intensities (arbitrary 
units) were measured by Kodak 1D Image Analysis Software (Eastman 
Kodak, Rochester, NY). 
 
Statistical analysis. Statistical analysis was carried out by Two-way (trial x 
time) ANOVA with repeated measures on the time factor. If analyses 
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revealed a significant interaction, a Student Newman-Keuls test was used 
to locate specific differences. Significance was accepted as P < 0.05. Data 
are means ± SE. All statistics were completed using Statistica software for 
windows (StatSoft, version 5.1, 1997, Statistica, Tulsa, OK). 
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5.3 Results  
Muscle Glycogen. Resting muscle glycogen was higher (P < 0.05) in Con 
compared with LCHO (375 ± 35 versus 163 ± 27 mmol glycosyl units•kg-1 
dry mass for Con and LCHO, respectively) and was reduced (P < 0.05) to 
102 ± 32 vs. 17 ± 5 mmol glycosyl units•kg-1 dry mass for Con and 
LCHO, respectively. 
 
Nuclear Abundance of Signalling Proteins. The nuclear abundance of total 
JNK was neither affected by glycogen nor contraction. Exercise increased 
(P < 0.05) phosphorylation of JNK in the nucleus compared with basal 
levels, but the degree of increase was not different when comparing trials 
(Figure 5.1). The nuclear abundance of NFκB and NFAT was neither 
affected by glycogen availability or contraction (Figure 5.2). 
 
No difference was observed in nuclear total p38 MAPK either before or 
after exercise in either trial. However, the phosphorylated form of p38 
MAPK was higher (P < 0.05) in LCHO compared with Con both before and 
after exercise. Despite this, the cytosolic abundance of phosphorylated 
p38 MAPK was not different between trials, although it tended (P = 0.09) 
to be higher in LCHO compared with Con after exercise (Figure 5.3).  
 
Exercise resulted in an increase (P < 0.05) in IL-6 mRNA in both CON and 
LCHO. However, the exercise-induced increase was markedly exacerbated 
(P < 0.05) in LCHO (Figure 5.4). When the pre-exercise nuclear 
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abundance of phosphorylated p38 MAPK was plotted against the exercise-
induced increase in IL-6 mRNA, a highly significant correlation (r = 0.96; 
P < 0.01) was observed (Figure 5.4). 
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Figure 5.1 Nuclear abundance of total (A) and phosphorylated (B) c-jun 
amino terminal kinase isoforms 1 and 2 (JNK 1/2) before (basal) and after 
(contraction) 60 minutes of concentric exercise with normal (CON; filled 
bars) or low (LCHO; open bars) pre-exercise muscle glycogen content. † 
Difference (P < 0.05) from basal (main time effect). Values are means ± 
SE (n = 8). 
A 
B 
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Figure 5.2 Nuclear abundance of nuclear factor kappa B (NFκB; A) and 
nuclear factor of activated T cells (NFAT; B) before (basal) and after 
(contraction) 60 minutes of concentric exercise with normal (CON; filled 
bars) or low (LCHO; open bars) pre-exercise muscle glycogen content. 
Values are means ± SE (n = 8). 
A 
B 
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Figure 5.3 Nuclear abundance of total (A) and phosphorylated (B) p38 
mitogen activated protein kinase (p38 MAPK) and cytosolic abundance of 
phosphorylated p38 MAPK (C) before (basal) and after (contraction) 60 
minutes of concentric exercise with normal (CON; filled bars) or low 
(LCHO; open bars) pre-exercise muscle glycogen content. * Difference (P 
< 0.05) in LCHO compared with CON. Values are means ± SE (n = 8). 
A 
B 
C 
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Figure 5.4 Exercise induced fold change in interleukin-6 (IL-6) mRNA 
with normal (CON; filled bars) or low (LCHO; open bars) pre-exercise 
muscle glycogen content (A) and the relationship between pre-exercise 
p38 MAPK and the exercise induced fold change in IL-6 (B) mRNA. * 
Difference (P < 0.05) in LCHO compared with CON. 
A 
B 
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5.4 Discussion  
The results from the present study suggest that low intramuscular 
glycogen is associated with the phosphorylation of the nuclear p38 MAPK. 
Since the phosphorylation of p38 in the nuclear fraction prior to exercise 
was associated with the exercise-induced fold increase in IL-6 mRNA, it 
appeared that one role of phosphorylation of p38 MAPK within the nucleus 
was to act as an upstream target for IL-6 in contracting human skeletal 
muscle.  
 
From our results, it appears that a diet low in carbohydrate that results in 
low intramuscular glycogen per se does not lead to the nuclear 
translocation of p38 MAPK, but rather phosphorylates p38 MAPK that 
resides in the nucleus (Figure 5.3). Subjects performed the same pre-trial 
exercise regime, so the increase in pre-exercise nuclear p38 MAPK 
phosphorylation observed in LCHO cannot be attributed to prior contractile 
activity. However, we cannot rule out the possibility that a high fat diet 
and not low glycogen per se was responsible for this observation because 
subjects ingested a high fat diet in the intervening period between the 
glycogen depleting exercise and the experimental trial in LCHO. Indeed, 
chronic exposure of human skeletal muscle cells to palmitate, a saturated 
fatty acid, increases the activation of p38 MAPK (Aas et al., 2004); 
whereas treatment with the unsaturated fatty acid, oleate, promotes a 
reduction in phosphorylation of this kinase and hence its activity (Aas et 
al., 2006). At the present time, there are no data that have examined the 
direct effect of low glycogen on p38 MAPK phosphorylation in skeletal 
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muscle, so we are unable to shed further light on whether our observation 
of nuclear p38 MAPK phosphorylation was due to low glycogen per se. Of 
note, however, Polekhina et al. (2003) have demonstrated that the AMP-
activated protein kinase (AMPK) β subunit contains a functional glycogen 
binding domain. In addition, when glycogen binds to this domain, the 
activity of AMPK and its upstream kinase AMPK-kinase is down-regulated 
(Steinberg et al., 2006). Although highly speculative, it is possible that 
kinases upstream of p38 MAPK, such as MKK3 and MKK6, may also have a 
functional binding domain that inhibits phosphorylation when bound to 
glycogen, although it must be noted that p38 MAPK phosphorylation in the 
cytosolic fraction was unaffected by glycogen content before exercise. 
Alternatively, the up-regulation of p38 MAPK in the presence of low 
glycogen may be a direct effect of AMPK activity as it has been 
demonstrated that the AMPK activator AICAR increases p38 MAPK 
phosphorylation in skeletal muscle (Lemieux et al., 2003).  
 
It is well established that when muscle cells are incubated with 
inflammatory agents such as LPS (Frost et al., 2002; Frost et al., 2003), 
reactive oxygen species (Kosmidou et al., 2002) IL-1β and TNF-α (Frost et 
al., 2003; Luo et al., 2003), IL-6 can be activated by JNK (Frost et al., 
2003), NFκB, and AP-1 (Kosmidou et al., 2002), which associates with 
NFAT to activate IL-6. Since it has been shown that the calcium 
ionophore, ionomycin, can induce IL-6 mRNA in human cultured muscle 
cells (Keller et al., 2002b; Keller et al., 2006), we hypothesized that NFAT 
would be activated by cytosolic Ca2+ accumulation upon contraction and 
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that this would lead to IL-6 gene transcription. From our results, this does 
not appear to be the case. Although the nuclear abundance of NFAT 
appeared to be higher in LCHO prior to exercise, this was largely due to 
the results obtained from one subject. Moreover, there was a 20-fold 
increase in the mRNA abundance of IL-6 in CON, but in these 
circumstances no increase in nuclear NFAT was observed. Therefore, while 
we cannot rule out the possibility that the rapid IL-6 gene transcription 
seen at the onset of contraction is mediated by NFAT secondary to 
increased cytosolic Ca2+ accumulation, our results are not consistent with 
this hypothesis. Likewise, there was no indication that NFκB mediated the 
increase in IL-6 mRNA during contraction. It is well known that NFκB is 
involved in the regulation of a large number of genes that control various 
inflammatory responses including IL-6 (Li et al., 2000b), while in skeletal 
muscle cell culture, NFκB induced IL-6 transcription appears most 
sensitive to incubation with LPS (Kosmidou et al., 2002). As discussed, 
however, the present study involved 60 minutes of concentric exercise 
that does not result in inflammation. Therefore, we were not surprised 
that the nuclear abundance of NFκB was not increased. In addition, as 
discussed previously, Cai et al (2004) showed in a mouse model with 
constitutive IKK expressed in skeletal muscle, IL-6 is not elevated, 
arguing against the NFκB pathway activating IL-6 in this tissue. However, 
it must be pointed out that, in this study, we measured nuclear abundance 
of NFκB and not the activity level of this protein by mobility shift analysis 
or phosphorylation of IκB. Therefore, our data cannot rule out the 
possibility that nuclear NFκB was activated in the nucleus by contraction. 
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In our experiment, nuclear JNK 1/2 phosphorylation was increased by 
contraction in both CON and LCHO (Figure 5.1), a result consistent with 
previous experiments that measured JNK activity in crude muscle 
homogenates from humans subjected to 60 minutes of cycling exercise 
(Aronson et al., 1998). Although the exercise induced increase in nuclear 
JNK 1/2 phosphorylation was similar when comparing the two trials, it is 
possible that JNK phosphorylation at the onset of exercise is an upstream 
signal for IL-6 gene transcription during contraction of this type. As 
discussed, Frost et al. (2003) has demonstrated that IL-6 gene expression 
is a downstream target of JNK in C2C12 myoblasts subjected to LPS. 
Clearly the hypothesis that JNK may mediate IL-6 gene transcription in 
contracting skeletal muscle is plausible and warrants further examination. 
 
The most important finding of this study was that the increase in 
phosphorylation of p38 MAPK in the nucleus due to low glycogen was 
associated with the magnitude of the increase in IL-6 mRNA (Figure 5.4). 
We acknowledge that the subject number is relatively low, but the 
tightness of this relationship suggests that phosphorylation of p38 MAPK 
at the nucleus may result in regulation of co-repressors or -activators 
binding to the 5’ flanking region of the IL-6 gene. This result stimulated us 
to examine this process further (see Chapter 6).  
 
In conclusion, we have shown that dietary manipulation that resulted in 
low intramuscular glycogen was associated with the phosphorylation of 
the nuclear p38 MAPK. In addition, the phosphorylation of p38 MAPK in 
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the nuclear fraction, before exercise was tightly related to the exercise-
induced fold increase in IL-6 mRNA.  
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CHAPTER SIX 
 
 
 
 
THE CALCIUM IONOPHORE, A23187 STIMULATES 
IL-6 GENE EXPRESSION IN CULTURED MYOTUBES, 
A RESPONSE THAT IS ABOLISHED WITH p38 
MAPK INHIBITION  
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6.1 Introduction 
In accordance with the literature, our previous findings described in detail 
in Chapters 3 & 4, have clearly shown that the production of IL-6 during 
“non-damaging” exercise is not related to inflammation or other cytokines, 
but rather is related to the intramuscular glycogen levels and the mode of 
contraction. Like other tissues, the constitutive expression of cytokines 
within skeletal muscle are usually minimal or absent at a resting state 
(Frost et al., 2002). Exercise induces a rapid increase of the nuclear 
transcriptional rate of IL-6 (Keller et al., 2001b), and its release into the 
circulation (Febbraio and Pedersen, 2002). Once in the circulation, IL-6 
has been reported to have a relative short half-life (Castell et al., 1988; 
Suzuki et al., 2000) and exhibit a rapid plasma clearance by the kidneys 
and the liver (Febbraio et al., 2003a; Montero-Julian et al., 1995), 
suggesting this cytokine may be largely regulated at the level of 
expression.  
 
Muscular contraction is a potent stimulus for Ca2+ release from the lateral 
sacs of the sarcoplasmic reticulum (Olson and Williams, 2000b), and 
elevated levels of Ca2+ have been shown to implicate in the transcription 
of IL-6 (Holmes et al., 2004; Keller et al., 2002b). In addition, contractile 
activity is known to result in phosphorylation and activation of the MAPK, 
p38 (Dentel et al., 2005). In the previous Chapter, we reported that the 
phosphorylation of p38 MAPK in the nucleus closely correlated with the 
expression of IL-6. Therefore, we hypothesized that the elevated levels of 
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Ca2+ might be serving as an upstream signal to activate the p38 MAPK, 
which then upregulates the expression of IL-6 in skeletal muscle. To test 
the hypothesis, we moved to a tissue culture experimental model, where 
we could carefully control the experimental environment. Accordingly, L6 
myotubes were stimulated with the calcium ionophore, A23187, in the 
presence of the p38 MAPK inhibitor, samples collected at the end of the 
experiment were subjected to Western blotting and RT-PCR analyses.   
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6.2 Materials and Methods  
Cell culture experiments. L6 myoblasts were maintained at 37°C on 100 
mm collagen-coated plastic dishes in 5% CO2/95% O2 humidified air in α-
MEM + 10% foetal bovine serum (FBS) culture media + 1% penicillin-
Streptomycin (stock concentration: 10 000 units•ml-1 penicillin G, 10 000 
µg•ml-1 Streptomycin). Differentiation was induced by switching to 
medium containing 2% FBS when the myoblasts were ~90% confluent. 
Experimental treatments commenced after 7 days, by which time nearly 
all of the myoblasts had fused to form myotubes. The evening before 
experiments, cells were serum-starved in α-MEM +0.1% FBS. Experiments 
were performed the following morning in α-MEM media + 0.1% FBS 
containing 4% fatty acid free bovine serum albumin, the cells were 
treated with different doses of the calcium ionophore, A23187 for 6 hours 
as recommended (Keller et al., 2002b), the optimal treating dosage was 
determined by analysing the extracted RNA using RT-PCR with rodent 
specific probe/primers as described previously (Carey et al., 2003).  
 
In successive experiments, the overnight serum-starved myotubes were 
treated in 500 nmol•L-1 A23187, with or without the addition of 10 
µmol•L-1 of the p38 MAPK inhibitor, SB203580, employing the appropriate 
vehicles as controls. After 6 hours, cells were harvested. In one 
experiment (n = 6 plates for each treatment), the nuclear fractions of 
lysed cells were isolated and subsequently analysed for total and 
phosphorylated form of p38 MAPK as described in the previous chapter 
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(chapter 5). In a second experiment (n = 5-6 plates for each treatment), 
cells were lysed and extracted for RNA, and analysed using RT-PCR as 
described above. 
 
Statistics. Statistical analysis was carried out by Student t-test followed by 
Bonferroni correction. Significance was accepted as P < 0.02. Data are 
expressed as means ± SE. All statistics were completed using Prism 4 for 
windows (version 4.01, 2004, GraphPad Software Inc). 
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6.3 Results  
The calcium ionophore, A23187 induces the expression of IL-6 mRNA in L6 
myotubes following a dose-dependent manner, with significant induction 
(P < 0.05) observed starting at a dosage of 500 nmol•L-1  (Figure 6.1). 
 
Treatment of L6 myotubes with the A23187, and/or the pyridinylimidazole 
p38 MAPK inhibitor SB203580 did not affect nuclear p38 MAPK. However, 
treating cells with ionomycin increased (P < 0.05) phosphorylation of 
nuclear p38 MAPK while addition of SB203580 attenuated (P < 0.05) this 
response (Figure 6.2). As with previous experiments (Keller et al., 2002b), 
ionomycin treatment increased (P < 0.05) IL-6 mRNA. However, the 
addition of the SB203580 to the A23187 blunted (P < 0.05) this response 
(Figure 6.2). 
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Figure 6.1 The calcium ionophore, A23187 induced fold-increase of 
interleukin-6 (IL-6) mRNA expression in cultured L6 myotubes. Fold 
change in with normal. * Difference (P < 0.02) in treatment dosages 
compared with control. Values are expressed as means ± SE (n = 3). 
* 
* 
* 
Dosage (nmol•L-1) 
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A23187 - + + 
SB203580 - - + 
Figure 6.2 Ratio between phosphorylated and total p38 MAPK (A) and IL-
6 mRNA (B) in cultured L6 myotubes treated with the calcium ionophore, 
A23187 in the presence or absence of the pyridinylimidazole p38 MAPK 
inhibitor SB203580. * Difference (P < 0.05) compared with - A23187;  - 
SB203580 (vehicle control). † Difference (P < 0.05) compared with + 
A23187; + SB203580. Values are expressed as means ± SE (n = 6). 
A 
B 
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6.4 Discussion  
The present study demonstrated that pharmacological inhibition of p38 
MAPK phosphorylation results in a complete ablation of the IL-6 response 
in stimulated skeletal myotubes. We performed tissue culture experiment, 
in order to further examine the strong association of p38 MAPK 
phosphorylation and the level of IL-6 gene expression seen in the previous 
chapter (Chapter 5).   
 
Treatment of skeletal myotubes with calcium ionophore has been 
previously shown to increase IL-6 mRNA expression (Keller et al., 2002b), 
and since muscle contraction results in a rapid and marked increase in 
intracellular Ca2+, which is a powerful stimulus for the phosphorylation of 
p38 MAPK, we hypothesized that A23187 would also induce 
phosphorylation of p38 MAPK in L6 myotubes.  
 
Treatment of L6 myotubes with A23187 dose-dependently increased the 
mRNA abundance of IL-6, therefore its rate of transcription (Keller et al., 
2001b) with an effective dosage starting at 500 nmol•L-1 . While the same 
treatment had no effect on total nuclear p38 MAPK, A23187 
phosphorylated nuclear p38 MAPK and resulted in a marked increase in IL-
6 mRNA. Importantly, inhibition of p38 MAPK in the nucleus using 
SB203580, reduced the phosphorylation of nuclear p38 MAPK, and totally 
ablated the increase in IL-6 mRNA. Although our in vitro data cannot 
provide definitive proof that the increase in p38 MAPK phosphorylation in 
the nucleus and the subsequent increase in IL-6 mRNA seen in vivo were 
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due to dietary manipulation that resulted in low intramuscular glycogen. 
Indeed, our tissue culture experiments have no evidence for the role of 
glycogen in this process. In addition, the factors that affect gene 
transcription in vitro cannot be totally representative of what occurs in 
vivo due to the complexity of the in vivo model. 
 
Notwithstanding these limitations, our in vitro data provide evidence that 
the relationship between phosphorylation of nuclear p38 MAPK and the 
increase in IL-6 mRNA observed in Chapter 5, was not merely associative 
but that phosphorylation of p38 MAPK participated in the induction of IL-6 
mRNA. Although other MAPK signalling molecules such as JNK have been 
shown to be capable of increasing IL-6 mRNA (Frost et al., 2003), we are 
confident that our inhibitor (SB203580) was specific for p38 MAPK, since 
this compound has been shown to prevent p38 phosphorylation and no 
other protein kinase at the concentration used in this experiment (Davies 
et al., 2000). The control of IL-6 promoter activity is very complex and 
not fully categorized, despite it being the subject of numerous studies in 
various cell types including monocytes, endothelial cells, fibroblasts, HeLa 
cells, and lymphocytes (Keller et al., 1996). To our knowledge, no studies 
have examined the transcription factors that may bind to the IL-6 
promoter region in muscle cells to induce expression of this gene, but 
based on our results, we suggest that candidate transcription factors may 
be mediated by p38 MAPK. It is important to note, that the β-isoform of 
p38 MAPK contains an LPS kinase domain (Shi and Gaestel, 2002), and 
therefore, while our antibody detected both α and β-isoforms, it is more 
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likely that the β-isoform of p38 MAPK would be the isoform that may lead 
to the activation of IL-6. 
 
In summary, along with our previous finding that the phosphorylation of 
nuclear p38 MAPK was associated with low intramuscular glycogen level 
and IL-6 gene expression, the current study provides good evidence that 
phosphorylation of p38 MAPK in the nucleus may participate in the 
regulation of corepressors or coactivators binding to the promotor region 
of the IL-6 gene in skeletal muscle cells. 
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CHAPTER SEVEN 
 
 
 
 
A UNIQUE SIGNALLING PATHWAY FOR IL-6 GENE 
TRANSCRIPTION IN SKELETAL MUSCLE THAT IS 
ACTIVATED BY CALCIUM BUT NOT 
LIPOPOLYSACCHARIDE 
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7.1 Introduction 
The previous chapters have clearly showed that skeletal muscle cells are 
capable of synthesizing IL-6 in the absence of observable inflammation. In 
lipopolysaccharide (LPS)-stimulated macrophagic cells, it is clear that the 
expression of IL-6 is regulated via the Toll-like receptor (TLR)/NFκB 
pathway (de Waal Malefyt et al., 1991; Kreutz et al., 1997; Randow et al., 
1995). In these cells, binding of LPS to the Toll-like receptor (TLR)-4 
recruits myeloid differentiation primary-response protein 88 (MyD88) to 
its cytoplasmic domain. By acting as an adaptor molecule, MyD88 triggers 
a cascade of intracellular signalling consisting of IL-1 receptor-associated 
kinase (IRAK)-1, TNF-α receptor-associated factor (TRAF)-6, leading to 
the activation of the IkappaB kinase (IKK)-nuclear factor of κB (NFκB) 
pathway. NFκB is a transcription factor that usually resides in the cytosol 
under resting conditions, where its activity is highly restricted by the 
association with IkappaB (IκB), the inhibitory subunit of NFκB. Activation 
of IKK phosphorylates this inhibitory subunit at specific serine sites, 
targeting it for ubiquitination and hence subsequent proteasomal 
degradation, resulting in the activation of NFκB. The activated NFκB is 
then able to translocate into the nucleus, and exert its transcriptional 
effects on a variety of immunogenic genes including IL-1β, IL-6 and TNF-α 
resulting in the induction of the classic inflammatory response (Figure 7.1) 
(Akira, 2003; Akira and Takeda, 2004; Beutler, 2000; Guha et al., 2001; 
Kreutz et al., 1997; Li et al., 2000a; Liang et al., 2004a; Nam, 2006).  
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In contrast, the role of NFκB in the regulation of IL-6 gene expression in 
skeletal muscle cells remains largely controversial. Several studies have 
indicated that skeletal muscle cells may synthesize IL-6 via an NFκB-
dependent mechanism (Baeza-Raja and Munoz-Canoves, 2004; Kosmidou 
et al., 2002; Liang et al., 2004b; Rhind et al., 2002). However, 
constitutive activation of NFκB did not appear to alter the transcription of 
IL-6 in skeletal muscle (Cai et al., 2004), nor the nuclear localization of 
NFκB seemed to be affected after one hour of concentric exercise, as 
reported in previous chapter. Although, we did not obtain data regarding 
the activity of nuclear NFκB in response to contraction due to our study 
limitations, nonetheless, these findings indicated that a divergent 
signalling pathway might exist for IL-6 gene transcription in skeletal 
muscle. The primiary objective of the present study was to unravel the 
molecular mechanism for the regulation of IL-6 within skeletal myotubes, 
particularly the functional role of NFκB in this process. To achieve this, 
two well-characterized murine cell-lines: C2C12 myotubes and RAW 264.7 
macrophages were chosen for the study, in which the LPS-stimulated 
macrophages were serving as a positive reference for NFκB activation.  
 
Despite the inherent limitations, in the present study we used Ca2+ release 
as a proxy for contraction. At the time of submitting this thesis, work in 
our laboratory has established a technique for contracting muscle cells in 
culture and we have been able to show similarities between contracting 
cells in culture and using calcium ionophores on many signalling 
parameters (data not shown). In the current study, we proposed that 
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skeletal muscle cells are able to synthesize IL-6 in response to increased 
cytosolic Ca2+ independent of NFκB activation. This hypothesis was based 
on the data presented in Chapter 6, where we observed that the Ca2+ 
ionophore A23187 increased the IL-6 mRNA abundance, but that this was 
blocked by inhibition of p38 MAPK. As discussed, p38 MAPK is not a 
transcription factor but is involved in the signal transduction of 
calcineurin/NFAT (Fiedler and Wollert, 2004), which is known to modulate 
cytokine gene expression (Dolmetsch et al., 1998; Fisher et al., 2006; Im 
and Rao, 2004; Olson and Williams, 2000a). Of note, in a recent study, 
inhibition of the NFAT upstream regulator, calcineurin impaired the Ca2+-
induced IL-6 response in cultured skeletal myotubes (Keller et al., 2006). 
Therefore, the second aim of the study was to examine whether NFAT 
may be responsible for the transcription of IL-6 in skeletal myotubes. 
Based on the literature and data collected in previous chapters from this 
thesis, we proposed a signal trandsuction hypothesis summarised in 
Figure 7.1 where LPS stimulated macrophages activate inflammatory 
cytokines via NFκB in the classical manner, but that Ca2+, signalling 
through p38 MAPK and calcineurin acts through NFAT to stimulate IL-6 
gene transcription. 
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Figure 7.1 The proposed cytokine signalling pathways for macrophage 
(left) and skeletal muscle (right). CD14 is a membrane-associated 
glycosylphosphatidylinositol-linked protein expressed at the surface of 
macrophages, which acts as a co-receptor in concert with TLR 4 for the 
recognition of bacterial lipopolysaccharide. 
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7.2 Materials and Methods  
Cell culture. C2C12 cell line was kindly provided by Dr. Gregory Steinberg 
(St. Vincent Medical Research Institute, Melbourne), RAW 264.7 cell line 
was purchased from the American Type Culture Collection (ATCC) 
(Manassas, VA). The C2C12 myoblasts were grown in α-MEM + 10% 
foetal bovine serum (FBS) + 1% penicillin-Streptomycin (stock 
concentration: 10 000 units•ml-1 penicillin G, 10 000 µg•ml-1 
Streptomycin). The RAW 264.7 cells were maintained in DMEM low 
modified (SAFC Biosciences Pty. Ltd) supplemented with 10% FBS + 1% 
penicillin-Streptomycin. The cell lines were maintained at 37°C in a 
humidified incubator supplemented with 5% CO2. 
 
Differentiation of the myoblasts was induced by switching to medium 
containing 2% FBS when the myoblasts were ~90% confluent. 
Experimental treatments commenced after 7 days, by which time nearly 
all of the myoblasts had fused to form myotubes. The evening before 
experiments, cells were serum-starved in α-MEM + 0.1% FBS. 
Experiments were performed the following morning in α-MEM media + 
0.1% FBS, the cells were treated with either 1 µM of the calcium 
ionophore, A23187 (Sigma) or 100 ng•ml-1 of lipopolysaccharide (LPS) (E. 
coli O26:B6; Sigma), or combination of the two as previously optimized. 
RNA was isolated using RNeasy® Mini Kit (Qiagen, Australia) according to 
the Manufacturer’s protocol, quantified and reverse-transcribed, before 
subjected to real time-PCR analysis for gene expression as described in 
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previous chapters  (Chapter 4–6). All cytokines were analysed using 
Assays-on-Demand™ primer and probe mix (Applied Biosystems, USA). 
 
Western Blotting. The cells were washed twice in ice-cold PBS before 
lysing in ice-cold buffer (50 mM HEPES, 150 mM NaCl, 10 mM NaF, 1 mM 
Na3VO4, 5 mM EDTA, 0.5% Triton X-100, 10% glycerol (v:v), 100 µg•ml-1 
phenylmethylsulfonyl fluoride, 5 µl•ml-1 protease- and phosphatase 
inhibitor cocktail) and centrifuged at 4˚C at maximum speed for 30 
minutes, the protein containing supernatants were transferred to fresh 
microfuge tubes and kept frozen at –80˚C until analysis. Analyses of 
protein were then carried out using SDS-PAGE with equal amount of 
protein loading in each well as described in previous chapters, and 
antibody-binding was detected using ChemiDoc™ XRS System (Bio-Rad 
Laboratory Inc., Hercules, CA).  
   
NFκB inhibition. The overnight serum-starved cells were pre-incubated in 
medium containing various concentrations of parthenolide (Sigma) for one 
hour. The cells were washed before stimulated with 100 ng•ml-1 LPS. The 
stimulated cells were then harvested three hours later, and isolated 
proteins were subjected to Western blotting analysis. In successive 
experiments, the C2C12 myotubes were pre-incubated in 40 µM for one 
hour before stimulation with either A23187 or LPS for 3 hours and 
analysed in the same manner as described above. 
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NFκB silencing. Two siRNA sequences of murine NFκB were tested for their 
capacity to reduce the expression of NFκB protein in C2C12 myotubes. 
Gene silencing was achieved with equal efficacy with the following pairs of 
21-bp oligonucleotide sequences (accession number NM_008689, siRNA 
ID 155566 (seq 1) and siRNA ID 155568 (seq 2); Ambion, Austin, TX, 
USA). The oligonucleotide pairs were annealed and reconstituted in the 
supplied RNase-free water. A negative control siRNA was also employed to 
account for off-target effects. Cells were seeded onto 6-well plates one 
day before transfection. On the day of transfection, the cell culture 
medium was replaced to a serum- and antibiotic-free α-MEM media and 
75 pmol of the respective siRNA was added with Lipofectamine 2000TM 
(Invitrogen, Mount Waverley, VIC, Australia) to give a final concentration 
of 45 nmol•L-1. The transfection medium was removed after 16–20 hours, 
and cells were washed with phosphate-buffered saline (PBS) and 
differentiated as described. 
 
NFAT inhibition. The serum-starved C2C12 myotubes were pre-incubated 
in medium containing 1 µM of 11R-VIVIT (Calbiochem, EMD Biosciences, 
Inc, Darmstadt, Germany) for one hour as reported (Noguchi et al., 
2004b). After washing with 1 X PBS, the cells were stimulated with 1µM of 
ionomycin (Sigma) or 100 ng•ml-1 LPS for three hours before RNA were 
extracted, and analysed using RT-PCR described above. 
 
Statistics. Statistical analysis was carried out by student t-test coupled 
with Bonferroni correction and One-way ANOVA. If ANOVA revealed a 
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significant interaction, Student Newman-Keuls test was then used to 
locate specific differences. Significance was accepted as P < 0.05. Data 
are expressed as means ± SE. All statistics were completed using Prism 4 
for windows (version 4.01, 2004, GraphPad Software Inc). 
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7.3 Results  
Cytokine response in macrophage and muscle cells. Immunoblotting 
against the macrophage-specific antigen revealed that the presence of 
F4/80 positive cells in our C2C12 cell line is minimal (Figure 7.2). In the 
macrophage, the mRNA expression of IL-6, IL-1β and TNF-α increased 
dramatically (p < 0.05) in response to LPS treatment, but not to the 
calcium ionophore, A23187, while treatment with A23187 + LPS lowered 
the fold induction of IL-6 and IL-1β (p < 0.05), but not the expression of 
TNF-α (Figure 7.3). In skeletal myotubes, A23187 induced a significant 
increase in IL-6 mRNA (p < 0.05), but not TNF-α, while IL-1β was only 
detected at basal levels. LPS treatment lead to a moderate increase of IL-
6 mRNA expression (p < 0.05), that is further augmented in the presence 
of A23187 (p < 0.05) (Figure 7.4). 
 
Kinetics of the cytokine responses. In the macrophage, incubation with 
LPS induced a marked expression of IL-6 and IL-1β (p < 0.01) observed 
at three hours, followed by a significant decline thereafter, while the TNF-
α response is much more rapid, with significant increase detected as early 
as one hour (p < 0.01), reaching its peak at three hours before the 
decline at five hours (Figure 7.5). A23187 induced a rapid and marked 
expression of the IL-6 mRNA in the skeletal myotubes that was sustained 
over five hours (p < 0.05), while LPS treatment elicited an observable 
response of TNF-α and IL-1β at five hours (p < 0.05) (Figure 7.6).   
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NFκB inhibition and the cytokine responses. LPS stimulation lead to a 
marked phosphorylation of IκBα in the macrophage but not the skeletal 
myotubes (Figure 7.7). Time course experiment revealed that the 
phosphorylation of IκBα and IKK were potentiated in macrophage after 1-
hour incubation with LPS but not in skeletal myotubes, while A23187 
treatment did not appear to affect the phosphorylation of neither IκBα nor 
IKK when compared to control in all of the tested time points (Figure 7.8). 
Pharmacological inhibition of NFκB dose-dependently reduced the LPS-
induced phosphorylation of IκBα in both macrophage and skeletal 
myotubes, but no significant difference was observed in the A23187 
stimulated skeletal myotubes (Figure 7.9). Parthenolide administration 
resulted in total and partial inhibition (p < 0.01) of the cytokine gene 
expression in a RAW 264.7 cell and C2C12 myotubes, respectively (Figure 
7.10). 
  
NFκB-slicencing and the cytokine responses. Transfection of myotubes 
with silencing sequence against NFκB resulted in marked reduction 
(greater than 50%) in protein expression of each subunits, however, no 
significant difference in IL-6 expression was observed between the wild-
type and the NFκB-silenced myotubes in response to A23187 stimulation, 
nor the mRNA expression of TNF-α was affected by the silencing, while IL-
1β was only detected at basal levels (Figure 7.11).  
 
NFAT inhibition and IL-6 response. Ionomycin is another commonly used 
calcium ionophore that has been reported to be more effective than 
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A23187 (Liu and Hermann, 1978). Ionomycin induced a significant 
increase in IL-6 mRNA expression in the skeletal myotubes at both 1- and 
3-hours, the NFAT inhibitor, 11R-VIVIT dramatically potentiated the 
ionomycin-induced IL-6 expression (Figure 7.12). 
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Figure 7.2 Immunoblotting of the F4/80 antigen in C2C12 and 
RAW264.7. F4/80 is a macrophage-specific antigen that is used to check 
for macrophage contamination in the C2C12 cell line. 
C2C12 RAW264.7 
F4/80 antigen 
Empty lane 
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Figure 7.3 Cytokine gene expressions of IL-1β and IL-6 (A), and TNF-α 
(B) in murine macrophage cell. RAW264.7 cells were exposed to the 
calcium ionophore, A23187, LPS or the combination of both for 3 hours, 
total RNA was isolated for real-time PCR analysis. * Difference (P < 0.02) 
compared with vehicle and control; † Difference (P < 0.05) compared with 
LPS treatment. Values are expressed as means ± SE (n = 3).  
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Figure 7.4 Cytokine gene expressions of IL-1β and IL-6 (A), and TNF-α 
(B) in murine skeletal muscle cell. C2C12 myotubes were exposed to the 
calcium ionophore, A23187, LPS or the combination of both for 3 hours, 
total RNA was isolated for real-time PCR analysis. * Difference (P < 0.05) 
compared with vehicle and control; † Difference (P < 0.05) compared with 
A23187 and LPS treatments; ‡ Difference (P < 0.05) compared with LPS 
treatment. Values are expressed as means ± SE (n = 6).            
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Figure 7.5 Kinetic of cytokine response of IL-6 (A), TNF-α (B) and IL-1β 
(C) in macrophages. RAW264.7 cells were exposed to LPS, total RNA was 
isolated at various time points for real-time PCR analysis. * Difference (P 
< 0.01) compared with control of the respective time points; † Difference 
(P < 0.05) compared with 1 and 5 hours of LPS treatment; ‡ Difference (P 
< 0.05) compared with 1 hour LPS treatment. § Difference (P < 0.05) 
compared with 1-hour LPS treatment. Values are expressed as means ± 
SE (n = 6). 
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Figure 7.6 Kinetic of cytokine response of IL-6 (A), TNF-α (B) and IL-1β 
(C) in skeletal muscle cell. C2C12 myotubes were exposed to either 
A23187 or LPS, total RNA was isolated at various time points for real-time 
PCR analysis. * Difference (P < 0.05) compared with control and vehicle 
of the respective time points; # Difference (P < 0.05) compared with LPS; 
† Difference (P < 0.05) compared with 5 hours of A23187 treatment; ‡ 
Difference (P < 0.05) compared with the same treatment of other time 
points. Values are expressed as means ± SE (n = 6). 
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Figure 7.7 Immunoblotting of the phosphorylated-IκBa (serine 32) in 
C2C12 and RAW264.7. Wild type C2C12 myotube and RAW264.7 
macrophage were stimulated with LPS for 3 hours before whole cell 
lysates were collected for analysis. The phosphorylation of IκBα is a proxy 
measure of NFκB activation, the fold difference is expressed relative to the 
C2C12 (n = 3). * Difference (P < 0.05) compared with C2C12. 
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Figure 7.8 Immunoblotting of the phosphorylated-IκBα (serine 32) and -
IKK α/β (serine 180/181) in RAW264.7 and C2C12 myotubes. The cells 
were incubated with either A23187 (A) or LPS, whole cell lysates were 
collected at various time points (n = 4). IKK is the upstream kinase of 
IκBα, their phosphorylations are indicative of NFκB activation. 
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Figure 7.9 Immunoblotting of the phosphorylated-IκBa (serine 32) in 
RAW264.7 and C2C12 myotubes. The cells were pre-incubated in various 
concentrations of the NFκB inhibitor, parthenolide, for 1 hour prior to LPS 
stimulation, whole cell lysates were collected after 3 hours (A) (n = 3). 
C2C12 myotubes were pre-incubated in 50 µM of parthenolide for 1 hour 
before stimulation with either A23187 for 3 hours (B) (n = 3). The 
phosphorylation of IκBα is serving as a proxy measure of NFκB activation. 
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Figure 7.10 Pro-inflammatory cytokine response in RAW 264.7 (A) and 
C2C12 (B) cells. The cells were pre-incubated in the presence of the NFκB 
inhibitor, parthenolide for 1 hour before the addition of LPS or A23187, 
total RNA was isolated after 3 hours and analysed using real-time PCR. 
The level of gene expression is shown as mRNA fold change relative to 
control (n = 3). * Difference (P < 0.02) compared with control; † 
Difference (P < 0.02) compared pathernolode control; # Difference (P < 
0.01) compared with the same treatment in the absence of parthenolide. 
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Figure 7.11 The effect of NFκB-silencing on the expression of NFκB (A) and 
cytokine gene expressions (B) in skeletal muscle cells. The transfected 
C2C12 myotubes were exposed to either A23187 or LPS for 3 hours, total 
RNA was isolated and analysed using real-time PCR. The level of gene 
expression is shown as mRNA fold change relative to control (n = 3). * 
Difference (P < 0.01) compared with scramble sequence; † Difference (P 
< 0.01) compared with siRNA 1; # Difference (P < 0.02) compared with 
control and vehicle; ‡ Difference (P < 0.01) compared LPS treatment. § 
Difference (P < 0.01) compared with A23187.  
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Figure 7.12 The effect of NFAT inhibition on the expression of IL-6 in 
skeletal muscle cells. The C2C12 myotubes were pre-incubated with the 
NFAT inhibitor, 11R-VIVIT, for 1 hour prior to addition of either ionomycin 
or LPS for 1 (A) and 3 hours (B), total RNA was isolated for real-time PCR 
analysis. The level of gene expression is shown as mRNA fold change 
relative to control (n = 3). * Difference (P < 0.02) compared with control; 
† Difference (P < 0.01) compared with LPS treatment; ‡ Difference (P < 
0.001) compared with vehicle IONO treatment.  
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7.4 Discussion  
The present study demonstrated that the expression of IL-6, but not TNF-
α or IL-1β is inducible by elevation of intracellular Ca2+ levels in skeletal 
muscle cells, and that the expression of IL-6 appeared to be regulated via 
mechanisms other than those of the classic inflammatory pathway. In 
accordance with the previous findings (Holmes et al., 2004; Keller et al., 
2002b; Keller et al., 2006), treatment of murine myotubes with calcium 
ionophores (A23187 and ionomycin) markedly increased the IL-6 gene 
expression, confirming C2C12 myotubes (mouse) like those of human and 
rat (L6) origin can synthesize IL-6 in response to Ca2+ transients, and that 
calcium ionophores can be used as an in vitro proxy for contraction for IL-
6 expression. Importantly, the calcium ionophore induced IL-6 gene 
expression, occurred in the absence of activation of the NFκB signalling 
cascade, identifying a novel NFκB independent signal tranduction cascade 
in skeletal muscle cells.  
 
From our results, it appears that the cytokine response observed in 
skeletal muscle cells differs greatly from that observed in the macrophage. 
First of all, the calcium ionophore, A23187 induced a dramatic IL-6 
response in the skeletal myotubes, but not in macrophages. In contrast, 
the LPS-stimulated macrophage showed a robust increase in IL-6 and IL-
1β expression, while the same treatment in skeletal myotubes only 
resulted in a moderate increase in IL-6, while TNF-α and IL-1β remained 
at basal levels. Moreover, when applied together, A23187 appeared to 
antagonize the effect of LPS on IL-6 and IL-1β expression in 
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macrophages, but greatly potentiated the IL-6 and TNF-α response to LPS 
in myotubes. So far, there are no studies that have examined the direct 
effect of elevated intracellular Ca2+ level on the LPS-mediated cytokines 
expression in muscle, therefore, we are unable to shed further light on 
this observation. However, Chen and Lin-Shiau et al. (2000) have 
demonstrated that thapsigargin, a compound that increases intracellular 
Ca2+ concentrations via inhibition of the ER Ca2+ -ATPase resulting in 
depletion of the endoplasmic reticulum Ca2+ stores, profoundly potentiated 
the LPS-mediated TNF-α production in RAW 264.7, but not the calcium 
ionophores, A23187 or ionomycin providing evidence that factors other 
than those of altered cytosolic Ca2+ content may be contributing to our 
observation.  
 
Secondly, our time-course study revealed that, although of a much lower 
magnitude when compared with the LPS-stimulated macrophage, the 
kinetics of the IL-6 response in the myotubes occurred at a much faster 
rate with the highest increase detected as early as one hour which 
remained elevated after three hours of treatment before a decline was 
observed. Of note, at one and three hours where the most significant IL-6 
increase was observed, the mRNA expression of TNF-α and IL-1β were 
only detected at basal levels, even at time point whereby A23187 induced 
a significant TNF-α expression, IL-6 was only increased by < 100-fold 
indicating that the myotubes are producing IL-6 via a TNF-independent 
pathway. In contrast, the peak increase of IL-6 mRNA in the macrophages 
was not observed until after three hours of treatment, which was 
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accompanied by the peak expression of TNF-α and IL-1β, and that the 
three cytokines exhibited a similar kinetic over the course of the 
experiment. Given that both TNF-α and IL-1β are potent inducers of IL-6 
(Akira et al., 1993), it is possible that the delayed IL-6 peak observed in 
the macrophages may represent a TNF-α and IL-1β-dependent 
mechanism.  
 
In monocytes and macrophages, it has been demonstrated that LPS 
stimulates the production of pro-inflammatory cytokines via activation of 
the NFκB pathway (Akira, 2003; Akira and Takeda, 2004; Beutler, 2000; 
Guha et al., 2001; Kreutz et al., 1997; Li et al., 2000a; Liang et al., 
2004a; Nam, 2006), and that once produced, both TNF-α and IL-1-β have 
also been shown to activate the classical NFκB pathway (Nishikori, 2005) 
and positively regulate their own expressions (Brinkman et al., 1999; Ilyin 
et al., 2000). In the present study, LPS stimulation of the RAW 264.7 cells 
resulted in a marked phosphorylation of IκBα and IKK (Figure 7.8 & 7.9). 
However, when C2C12 myotubes were stimulated with LPS, the 
phosphorylation of IκBα and IKK was much less marked (Figure 7.8 & 
7.9). These data suggested that in macrophages the LPS-induced 
expression of IL-6 involves NFκB activation, while the activation of NFκB 
in skeletal myotubes seemed much less sensitive to LPS stimulation. Of 
equal importance was the observation that stimulation of C2C12 cells with 
A23187 had absolutely no effect on activation of the NFκB signalling 
cascade and yet such stimulation increased IL-6 mRNA expression nearly 
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1000 fold (Figure 7.4). Together, these observations suggest that the Ca2+ 
mediated IL-6 gene transcription is NFκB independent.   
 
As a collary to simply examining the effect of Ca2+ on NFκB and IL-6 
mRNA expression, we also used strategies to inhibit NFκB signalling in 
skeletal muscle. Accordingly, a pharmacological inhibitor of NFκB, 
parthenolide was used. Parthenolide mediates the inhibition of NFκB by 
preventing the activation of IKK without affecting the activation of JNK 
and p38 MAPK (Hehner et al., 1999; Nam, 2006). Pre-treatment of RAW 
264.7 cells with parthenolide blunted the LPS-induced NFκB activation in a 
dose-dependent manner, with a noticeable reduction observed starting at 
25 µM (Figure 7.9). Accordingly, LPS induced activation of cytokine mRNA 
expression was completely blunted by parthenolide treatment (Figure 
7.10). A23187 had no effect on NFκB activation (Figure 7.8 and 7.9), 
while parthenolide had no effect on this pathway either (Figure 7.10). It 
was very surprising, therefore, that treatment of myotubes with 
parthenolide blunted the A23187-induced IL-6 mRNA response. From 
these data we can only conclude that parthenolide is not a specific 
inhibitor of NFκB activation and that it must be working on other signal 
transduction pathways.  
 
Given these problems with the parthenolide experiments, it was necessary 
to try and specifically inhibit NFκB. Accordingly, we performed RNA 
silencing experiments. Transient transfection of C2C12 myotubes with 
small interfering RNA (siRNA) reduced the basal expression of the NFκB 
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protein by over 50% (Figure 7.11). Importantly, when stimulated, the 
A23187-induced IL-6 mRNA response in C2C12 myotubes was not 
different when comparing siRNA cells targeted to NFκB with cells 
transfected with the scramble sequence (negative control). While we 
acknowledge that our data cannot rule out the possibility that the residual 
expression of NFκB may be sufficient to maintain the cytokine response in 
the stimulated myotubes, they provide further evidence supporting the 
notion that skeletal muscle may utilise a different signalling mechanism 
for IL-6 gene transcription in muscle, and that the full expression of NFκB 
is not essential to initiate the transcription of IL-6 in response to Ca2+.  
 
Given that our data suggested that NFκB was not involved in Ca2+-induced 
IL-6 mRNA expression, we next examined whether NFAT was involved as 
shown in Figure 7.1. Accordingly, we treated cells with the NFAT inhibitor 
peptide, 11R-VIVIT. Treatment of cells with LPS in the presence or 
absence of 11R-VIVIT had no effect on IL-6 mRNA expression. In contrast, 
and contrary to our hypothesis, 11R-VIVIT enhanced, rather than 
repressed the Ca2+-induced IL-6 mRNA expression in a time-dependent 
manner. Give that NFAT is a transcription factor that is known to play a 
pivotal role in the activation of cytokine gene expression, including IL-6 
(Abbott et al., 2000; Rao et al., 1997), and that inhibition of NFAT 
(Nilsson et al., 2006) or its upstream regulator, calcineurin (Banzet et al., 
2007), has been shown to significantly reduce the transcription of the IL-6 
gene, this result was most surprising. The precise reason for this 
observation is currently unknown, but it is possible that our observation 
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may be attributed to the specificity of our inhibitor. Therefore, alternate 
approaches for inhibition in a well-characterized human muscle cell-line 
may be necessary to determine the role of NFAT in the Ca2+ induced 
increase in IL-6 mRNA expression.  
 
In summary, we have shown that the expression of IL-6 is differentially 
regulated in macrophages and skeletal myotubes. In skeletal myotubes, 
IL-6 may be activated by acute elevation in intracellular Ca2+ levels via an 
NFκB-independent mechanism, and that the IL-6 response precedes the 
appearance of TNF-α. Blockage of the NFAT pathway did not attenuate the 
IL-6 response to Ca2+ stimulation. Although the molecular mechanism for 
IL-6 gene activation in contracting skeletal muscle, particularly the role of 
NFAT, warrants further investigation, the current study identifies a 
divergent signalling pathway may exist for IL-6 gene transcription in 
skeletal muscle. 
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CHAPTER EIGHT 
 
 
 
 
SUMMARY AND CONCLUSIONS  
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8.1 Summary and conclusions 
The primary aim of this thesis was to investigate the intracellular 
mechanism for IL-6 gene transcription in skeletal muscle.  
 
The first study (Chapter 3) confirmed that human skeletal myocytes per 
se are a source of the contraction induced IL-6, and that the mRNA and 
protein expression of IL-6 was predominantly located in type 2 muscle 
fibres with high glycogen content. Although, this finding is contrary to 
previous findings that IL-6 mRNA expression and protein release are 
exacerbated with glycogen depletion, it is possible that during prolonged 
exercise as the type 1 fibres are becoming glycogen-depleted, the type 2 
fibres may be subsequently recruited. Nevertheless, this was the first 
study to identify that IL-6 is produced within muscle cells during muscular 
contraction because we measured the mRNA levels by in situ 
hybridisation.  
 
Given that the expression of IL-6 is known to be regulated by other 
cytokines, particularly those that are implicated in the inflammatory 
processes, the second study (Chapter 4) aimed to determine whether 
muscle contractions per se increase the expression of other cytokines 
within skeletal muscle, as well as the implication of carbohydrate 
availability in such a process. The second study (Chapter 4) demonstrated 
that cytokines are not ubiquitously expressed in human skeletal muscle, 
and like IL-6, the expression of IL-8 is also influenced by glycogen 
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availability within the contracting muscle, which provided further evidence 
that the transcription of IL-6 is related to metabolic processes rather than 
inflammation secondary to muscle damage. 
 
Having concluded from the first two studies that contraction induces the 
expression of IL-6 in skeletal muscle cells that is influenced by the 
availability of intramuscular glycogen levels, and that previous 
investigations have also consistently reported the activation of p38 MAPK 
in skeletal muscle during contraction, the third study (Chapters 5 & 6) 
sought to investigate the effect of reduced intramuscular glycogen levels 
on the activation of p38 MAPK, and subsequently the expression of IL-6, 
in response to “non-damaging” muscular exercise. From our results, it 
appeared that a reduction in intramuscular glycogen per se does not lead 
to the nuclear translocation of p38 MAPK, but rather phosphorylates 
nuclear p38 MAPK. Moreover in the human study, the phosphorylation of 
p38 MAPK in the nucleus appeared to be closely associated with the 
contraction-induced mRNA expression of IL-6. To determine whether this 
relationship was due to a casual or random association, it was necessary 
to perform tissue culture experiments (Chapter 6). We found that an 
elevation in intracellular Ca2+ phosphorylated the nuclear p38 MAPK which 
resulted in a marked increase in IL-6 mRNA expression. More importantly, 
pharmacological suppression of p38 mediated a total ablation of this 
response providing evidence that the relationship between 
phosphorylation of nuclear p38 MAPK and the increase in IL-6 mRNA was 
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not merely associative but that phosphorylation of p38 MAPK participated 
in the induction of IL-6 mRNA. 
 
Although, we have demonstrated that skeletal muscle cells express IL-6 in 
a p38 MAPK dependent manner, several studies have indicated that the 
cytokine transcription factor, NFκB may also be involved in the activation 
of IL-6 by acting in concert with p38 MAPK. In the next study (Chapter 7), 
we aimed to unravel the underlying mechanism for expression of IL-6 
within skeletal myotubes, with particular focus on the implication of NFκB 
in this process.  
 
Our data revealed that the pattern of cytokine response in skeletal muscle 
cells differs greatly from that in the macrophage. It appears that skeletal 
muscle cells are able to attain a maximal expression of IL-6 without TNF-α 
and IL-1β, which are the primary inducers of IL-6 during systemic 
inflammation, and that the activation of IL-6 in skeletal muscle seems to 
be regulated by an NFκB-independent mechanism (Figure 8.1). Given that 
NFκB plays a pivotal role in the activation of cytokine gene expressions in 
various immune cells, particularly macrophage cells, in response to 
pathological challenges, our observation further supports the notion that 
the expression IL-6 in muscle is not pathophysiological. Importantly, 
inhibition of the Ca2+ sensitive transcription factor, NFAT, not only failed to 
attenuate the effect of Ca2+, but surprisingly it potentiated the expression 
of IL-6 in the stimulated myotubes. Although, the exact reason for this 
observation is unknown at the present time, however, the role of NFAT in 
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this process is warrant for further investigations. The use of 
pharmacological agents to stimulate or inhibit signalling pathways in vitro 
is a useful and relatively basic technique to delineate biochemical 
signalling pathways. However, it is worth bearing in mind the limitations 
of this approach such as off-target effects that some of these compunds 
might have when planning for future experiments. 
  
In conclusion, the thesis demonstrated that the expression of IL-6 in 
skeletal muscle is regulated by a network of signalling cascades that is 
likely to involve crosstalk between the Ca2+ and glycogen/p38 MAPK 
pathways (Figure 8.1). Ongoing research is necessary to gain further 
insight into the molecular mechanism in which IL-6 is regulated in the 
contracting muscles. Understanding the regulation mechanism of this 
process not only would help explain some of the beneficial effects of 
physical exercise on health, it may also lead to IL-6 being used as a 
potential therapeutic aid in the treatment of metabolic diseases like type 2 
diabetes. 
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Figure 8.1 Summary of cytokine expression in macrophage and skeletal 
muscle. 
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